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ABSTRACT: POLYMERIC NANOCARRIERS DELIVERING ANTICANCER 
AGENTS FOR THE TREATMENT OF CHEMORESISTANT PROSTATE 
CANCER AND LUNG METASTATIC MELANOMA 
Ruinan Yang, Ph.D. 
University of Nebraska, 2018 
Supervisor: Ram I. Mahato, Ph.D. 
The aims of this thesis is to first develop novel combination chemotherapies 
of two anticancer agents and their appropriate drug delivery platforms to treat 
chemoresistant prostate cancer, and second develop a polymeric conjugate of a 
biodegradable polymer and novel tubulin destabilizer to treat lung metastatic 
melanoma.  
In Chapter 1, a general introduction of polymeric nanocarriers including 
polymeric micelles and polymer drug conjugates for cancer therapy was given. In 
Chapter 2, we described a combination therapy of paclitaxel (PTX) polymer 
conjugate and cyclopamine (CYP) polymer conjugate, which had the potential to 
treat chemoresistant prostate cancer. We first synthesized mPEG-b-PCC-g-PTX-
g-DC (P-PTX) and mPEG-b-PCC-g-CYP-g-DC (P-CYP) polymer-drug conjugates, 
which they self-assembled into micelles. The combination of P-PTX and P-CYP 
alleviated PTX resistance and suppressed tumor colony formation. Further, 
combination therapy inhibited Hedgehog (Hh) signaling and upregulated tumor 
suppressor miRNAs. We established orthotopic prostate tumor in nude mice and 
there was significant tumor growth inhibition in the group treated with the 
combination therapy of P-PTX and P-CYP compared with monotherapy. In 
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Chapter 3, we designed a novel microtubule destabilizer QW-296 and combined 
it with a newly synthesized Hh signaling inhibitor MDB5 to treat taxane-resistant 
prostate cancer. The combination of QW-296 and MDB5 exhibited stronger 
anticancer activity towards chemoresistant prostate cancer cells than single drug 
treatment, and the results revealed that they synergistically worked together via 
distinct but complementary mechanisms. To improve the translation and promote 
therapeutic efficacy of the two novel anticancer agents, we synthesized an 
amphiphilic copolymer mPEG-p(TMC-MBC) that could self-assemble into 
polymeric micelles and encapsulate two hydrophobic drugs with high drug loading. 
We established a model of orthotopic prostate tumor in nude mice to evaluate in 
vivo efficacy of QW-296, MDB5 and their combination. The results confirmed that 
combination of QW-296 and MDB5 in micelles showed maximum inhibition of 
tumor growth compared with monotherapy or combination therapy in co-solvent. 
In Chapter 4, we introduced a new microtubule destabilizer SMART-OH and its 
polymer-drug conjugate, methoxy-poly (ethylene glycol)-block-poly (2-methyl-2-
carboxyl-propylene carbonate-graft-SMART-graft-dodecanol) (abbreviated as P-
SMART). Similar to its parent drug, P-SMART showed significant anticancer 
activity against melanoma cells in cytotoxicity, colony formation, and cell invasion 
studies. In addition, P-SMART treatment led to cell cycle arrest at G2/M phase and 
cell accumulation in sub-G1 phase. We established a model of metastatic 
melanoma to the lung in C57/BL6 albino mice to determine in vivo efficacy of P-
SMART and SMART-OH at the dose of 20 mg/kg. P-SMART treatment resulted in 
significant inhibition of tumor growth and prolonged mouse median survival. In the 
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end, Chapter 5 summarized the featured results of this thesis and gave some 
suggestions for future studies. 
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CHAPTER 1 INTRODUCTION 
1.1 POLYMERIC NANOCARRIERS FOR CANCER TREATMENT  
Even though the overall cancer death rate has dropped by more than 20% 
over two decades, cancer accounts for the most common cause of death in the 
United States. Approximately, there are 439 new cases of cancer and 163 cancer 
deaths every 100,000 men and women per year. Globally, there were 14.1 million 
new cases and 8.2 million cancer-related deaths in 2012. These statistics indicate 
that progresses in preclinical research of cancer biology have slowly been 
translated into actual improvement in cancer therapy and much work still remains, 
which encourages more emerging collaborations among oncologists, cancer 
biologists, biomaterial scientists and biomedical engineers. Among various clinical 
therapies for cancer treatment, chemotherapy is still the mainstay, however, the 
inefficiency and side effects of chemotherapy associated with conventional 
formulations of anticancer small molecules are urgently needed to overcome. 
Many chemotherapeutic drugs have poor aqueous solubility, which requires 
appropriate formulation to assist solubilization when intravenous administration 
needed. Cremophor EL, for example, is the formulation vehicle for paclitaxel and 
also known to exert a range of side effects even including anaphylactoid 
hypersensitivity and nephrotoxicity [1]. Off-target to the site of interest and wide 
biodistribution via bloodstream of anticancer agents also attribute to inefficiency of 
chemotherapy, suggesting the ideal formulation should have the capability to 
deliver and release drugs precisely at the target sites in a sustained and controlled 
manner. 
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Nanomedicines have been no doubt gaining tremendous recognition as 
indispensable tools to assist and boost chemotherapies and other traditional 
cancer therapies. They are designed to much elevate water solubility of given 
drugs, provide selective delivery of anticancer agents to target tumor site, and has 
the potential to alter the pharmacokinetics of those drugs leading to extended 
blood circulation time and accumulation at the site of action.  A variety of innovative 
nano-delivery platforms such as polymeric nanocarriers, liposomes, dendrimers, 
nano-hydrogels have been developed and applied to deliver specific anticancer 
agents including small-molecular-weight drugs, proteins, peptides and genes. 
Synthetic polymer-based nanocarriers have been extensively investigated among 
a variety of nanocarrier systems due to their amphiphilic characters and chemical 
versatility [2]. This chapter will mainly focus on the introduction and recent research 
progress of polymeric micelles and polymer-drug conjugates. 
1.2 POLYMERIC MICELLES  
Polymeric micelles, which were initially introduced by Ringsdorf in 1984 [3], 
are assembled by amphiphilic block copolymers in aqueous milieu. They are 
characterized by the core-shell architecture, where hydrophobic composition are 
segregated from hydrophilic exterior to form an inner core. Core segregation from 
aqueous solvent is the major driving force for micelle formation along with a variety 
of intermolecular forces such as hydrophobic interaction, electrostatic interaction, 
and hydrogen bonding [4-13]. Several advantages of polymeric micelles make 
them favorable drug carriers compared with conventional dosage forms. First, 
polymeric micelles have a size range from several tens to a hundred of nanometers 
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with a narrow distribution, which can help micelles avoid from rapid renal clearance 
and retain in the target tissue with an enhanced permeation retention (EPR) effect 
involved [14]. Second, the amphiphilic character of micelles protects hydrophobic 
drugs in of the core from degradation of hydrolytic enzymes, and accounts for 
relatively prolonged retention time in blood circulation. It has been reported that 
nanoformulations with hydrophobic outer surfaces tend to be easily taken up by 
reticuloendothelial system (RES) or mononuclear phagocyte system (e.g. 
monocytes and macrophages) [15,16], whereas those with hydrophilic surfaces 
could minimize protein adsorption, prevent unwanted aggregation between 
micelles, and show increased circulation time [17]. Furthermore, shell surface of 
polymeric micelles can be decorated by a variety of functional groups facilitating 
receptor-mediated drug delivery. Poly(ethylene glycol) (PEG) has been widely 
used as hydrophilic backbone of polymeric micelles due to their biocompatible 
hydrophilic nature and the stealth behavior resulting in reduced interaction with 
plasma proteins and cell-surface proteins [18-20].  
1.3 POLYMER-DRUG CONJUGATES 
Polymer and anticancer drug conjugates have also drawn extensive 
attention to researchers for cancer therapy from bench side to bedside. Generally, 
the design of polymer conjugates is to chemically combine drug molecules to an 
amphiphilic block polymer to form a macromolecular prodrug. Although, the 
conjugated drug may lose some therapeutic activity in the form of the prodrug, 
there are several advantages of the conjugates over corresponding parent drugs 
such as less side effects, enhanced accumulation to site of interest and improved 
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patient compliance, which makes polymer-drug conjugates have become a fast-
growing application in clinical studies. Similar with polymeric micelles, PEG is one 
of the most common hydrophilic polymers to be selected as hydrophilic blocks, 
because it has chemical flexibility of the chain in favor of subsequent conjugation 
and it is approved by FDA for human use [21]. However, PEG only has two terminal 
groups able to conjugate with drugs, thus the selection of hydrophobic segment 
for PEG copolymer are mainly based on its drug conjugating capacity that enables 
reaction with reactive groups on the drug molecule. A variety of monomers that 
have reactive groups such as OH, COOH, NH2, CH=CH2, C≡CH can be introduced 
the polymer chains [22-27]. The linker or the spacer between polymer and small 
molecule are supposed to be relatively stable during transport in physiological 
condition and hydrolysed at the site of target. In contrast with PEG, N-(2-
hydroxypropyl)-methacrylamide copolymers (HPMA), another widely used 
hydrophilic block, has multiple reactive groups and can be simultaneously 
functionalized with therapeutic agents, targeting moieties as well as imaging 
moieties. Typically, a lysosomally degradable peptidyl Gly-Phe-Leu-Gly is most 
commonly used linker for HPMA drug conjugation.  
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CHAPTER 2 COMBINATION THERAPY OF PACLITAXEL AND 
CYCLOPAMINE POLYMER-DRUG CONJUGATES TO TREAT 
ADVANCED PROSTATE CANCER1 
2.1 INTRODUCTION 
Prostate cancer is the second leading cause of cancer-related deaths in 
American men. Although androgen deprivation therapy (or androgen suppression 
therapy) is effective in treating prostate cancer in early stage [28], shrunken tumors 
often become androgen-independent at 18-24 months post-treatment [29], leading 
to aggressive and metastatic forms of prostate cancer, also known as hormone 
refractory prostate cancer (HRPC). Taxane (docetaxel and paclitaxel (PTX)) is one 
of the standard therapies for HRPC [30]. While these anticancer agents have 
shown significant efficacy at the initial stage of chemotherapy, the long-term 
efficacy is limited and patients will suffer from relapse owing to the development of 
chemoresistance [31-35]. Therefore, there is an urgent need to improve the long-
term efficacy of current chemotherapy.  
Hedgehog (Hh) signaling influences the initiation and progression of cancer 
and is needed for regeneration of prostate epithelium through crosstalk with 
androgen signaling [36-39]. Therefore, the inhibition of Hh pathway has the 
potential to induce anti-proliferative and apoptotic effect on prostate cancer cells. 
Furthermore, Hh signaling involves in the initiation and development of cancer 
                                                          
1 R. Yang, G. Mondal, D. Wen, R.I. Mahato, Combination therapy of paclitaxel and cyclopamine 
polymer-drug conjugates to treat advanced prostate cancer, Nanomedicine. (2016) 
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stem cells (CSCs), which are a distinct subset of cancer cells with self-
renewal/differentiation and tumorigenic potentials [40-42]. Thus, depleting CSCs 
at the early stage is essential to inhibit tumor growth and metastasis. 
Cyclopamine (CYP), a naturally occurring antagonist of Hh signaling, binds 
to cell surface receptor smoothened (SMO) resulting in suppression of SMO 
activity and inhibition of Hh signaling pathway [43,44]. CYP has shown to inhibit 
the proliferation of DU145, PC3 and 22RV1 cells and reduce tumor growth in mice 
[45,46]. In this regard, a combination therapy of PTX and CYP could have 
synergistic therapeutic efficacy of treating advanced prostate cancer and also lay 
the foundation for promising chemotherapy. However, these drugs are highly 
hydrophobic, which require an appropriate drug delivery system, such as 
liposomes, nanoparticles and micelles, for their formulation and delivery to the 
tumor after systemic administration. Polymer-drug conjugates acquire wide 
attention and some of them are undergoing clinical trials or ready to reach the 
market [47-52]. Unlike physically drug encapsulated liposomes, nanoparticles and 
micelles, polymer-drug conjugates prevent premature drug release and undesired 
toxicities as covalently linked polymer-drug conjugates are more stable in the 
circulation and release drugs in a controlled manner at the tumor site with 
therapeutically effective concentration. Moreover, covalent drug conjugation to 
polymers achieves enhanced drug payload compared to physically encapsulated 
micelles or nanoparticles. Additionally the nano-size ensures preferential 
accumulation of these conjugates in tumor cells via the enhanced permeability and 
retention (EPR) effect [53].  
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In our previous studies [54], we synthesized poly (ethylene glycol)-block-
poly (2-methyl-2-carboxyl-propylene carbonate) (mPEG-b-PCC) for drug delivery. 
In this study, we conjugated PTX and CYP to the carboxyl pendant groups of 
mPEG-b-PCC (Mw: mPEG 5000 Da, PCC 4480 Da, 28 units). Besides PTX and 
CYP, the final polymeric conjugates consist of three components, biocompatible 
PEG blocks, a biodegradable polycarbonate backbone and dodecanol (DC) lipid 
chains. PEG ensures the stealth properties of polymeric conjugates and the 
polycarbonate backbone has low toxicity since its degradation products are CO2 
and alcohol. In addition, DC can increase requisite hydrophobicity and thus assist 
in self-assembly into nano-sized micelles. This conjugation strategy has the 
potential to effectively deliver drugs to tumors after systemic administration and 
treat orthotopically implanted prostate cancer in mice by killing both bulk tumor 
cells and CSCs. 
2.2 METHODS 
2.2.1 Synthesis of mPEG-b-PCC-g-PTX-g-DC (P-PTX) 
Synthesis scheme of polymer-drug conjugates is illustrated in Figure 1. 
Monomer 2-methyl-2-benzyloxycarbonyl-propylene carbonate and its copolymer 
with mPEG (mPEG-b-PBC) were synthesized by ring opening polymerization 
followed by hydrogenation to obtain the copolymer containing carboxyl pendent 
groups (mPEG-b-PCC) as previously described. PTX and DC were conjugated to 
the carboxyl groups of mPEG-b-PCC polymer using carbodiimide coupling. 
mPEG-b-PCC (75 mg, 0.0079 mmol) was dissolved in anhydrous dichloromethane 
(DCM) followed by addition of PTX (54 mg, 0.063 mmol), DCC (65 mg, 0.31 mmol), 
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DMAP (29 mg, 0.24 mmol). The reaction was stirred for three days under nitrogen 
atmosphere at 4°C and then DC (23.5 mg, 0.12 mmol) was added and the reaction 
was allowed to proceed for another two days (Figure 1A). Crude product was 
purified by precipitation in large excess of diethyl ether and then by dialysis against 
hanol using a regenerated cellulose membrane with 7K MWCO.  
2.2.2 Synthesis of mPEG-b-PCC-g-CYP-g-DC (P-CYP) 
Synthesis of Boc-β-Ala-TT.  Boc-β-Ala-OH (94.6mg, 0.5 mmol), 2-
mercaptothiazoline (59.6 mg, 0.5 mmol) and DMAP (61.1 mg, 0.5 mmol) were 
dissolved in DCM under nitrogen protection. The solution was first stirred for 5 min 
-10 °C followed by adding EDCI (95.9 mg, 0.5 mmol) and the solution was stirred 
at -10 °C for 3 h and another 14 h at room temperature. After reaction, 40 mL DCM 
was added and the solution was washed with NaHCO3 aq. (0.1 M), HCl (0.1 M) 
and then NaCl aq. The organic layer was dried by Na2SO4 and the crude product 
was purified by column chromatography (silica gel 60 Å, 200-400 mesh, EtOAc: 
CH3OH 15: 1) and then recrystallized from DCM to give yellow powder. The 
structure was confirmed by 1H-NMR spectroscopy. 
Synthesis of Boc-β-Ala-CYP.  Boc-β-Ala-TT (107 mg, 0.37 mmol) and CYP 
(76 mg, 0.18 mmol) were dissolved in pyridine under nitrogen atmosphere. The 
solution was stirred at 50 °C for 28 h and then the solvent was removed by rotary 
evaporation. The crude product was purified by column chromatography (silica gel 
60 Å, 70-230 mesh, EtOAc: Hexane 7:3) to give solid of Boc-β-Ala-CYP in 75 % 
yield. The structure was confirmed by 1H NMR spectroscopy and LC-MS.  
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Synthesis of NH2-β-Ala-CYP. Boc-β-Ala-CYP was dissolved in anhydrous 
DCM (3 mL) and TFA (3 mL) was added at 0 °C. The resulting solution was left 
stirring overnight to ensure complete Boc removal. Excess TFA was removed by 
nitrogen flushing. The resulting compound was dissolved in chloroform (15 mL) 
and washed with aqueous saturated NaHCO3 (3 x 20 mL) and brine (1 x 20 mL). 
The organic layer was dried over anhydrous sodium sulfate and filtered. NH2-β-
Ala-CYP was obtained after the solvent was removed by rotary evaporation. The 
structure was confirmed by 1H NMR spectroscopy and LC-MS. 
Synthesis of P-CYP. mPEG-b-PCC (123 mg, 0.013 mmol) was dissolved in 
anhydrous DCM followed by the addition of NH2-β-Ala-CYP (50 mg, 0.10 mmol), 
EDCl (50 mg, 0.25mmol), HOBt (35 mg, 0.25 mmol). The reaction was stirred for 
two days under nitrogen atmosphere at the room temperature. Then, DC (48.3 mg, 
0.25 mmol) was added and the reaction was allowed to proceed for another two 
days (Figure 1B). After completion of the reaction, crude product was purified by 
precipitation in large excess of diethyl ether. The precipitate was then purified by 
dialysis against ethanol using a regenerated cellulose membrane with 3,500 
MWCO.  
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2.2.3 Characterization of polymer-drug conjugates 
1H NMR spectra were recorded on a Bruker (500 MHz, T = 25 °C) using 
DMSO-d6 as a solvent for P-PTX and Chloroform-d as a solvent for P-CYP in a 
chemical shift range of 0-12 ppm. 
2.2.4 Preparation and characterization of polymer-drug conjugate micelles 
The film hydration method was used for preparing P-PTX and P-CYP 
conjugate micelles. Briefly, 10 mg of P-PTX or P-CYP was dissolved in 
 
 
Figure 1. Synthetic scheme of two polymer-drug conjugates. (A) mPEG-b-PCC-
g-PTX-g-DC (P-PTX) and (B) mPEG-b-PCC-g-CYP-g-DC (P-CYP). 
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dichloromethane (DCM) and the solvent was evaporated under reduced pressure. 
The resulting film was hydrated with 1 ml of phosphate buffered saline (PBS; pH 
7.4) followed by sonication and filtration through 0.22 μm filter. Mean particle size 
was measured by using a Zetasizer Nano ZS90 (Malvern, Worcestershire, UK) at 
a scattering angle of 173°. A total of 12 measurements were taken per sample with 
a time span of 10 s. Particle size distribution was reported as the mean ± SEM. of 
three independent samples. Critical micelle concentration (CMC) of P-PTX and P-
CYP was determined using pyrene as a hydrophobic fluorescent probe as 
described previously [54].  
PTX or CYP encapsulated micelles were also prepared by film hydration 
method. Briefly, 1 mg of PTX or CYP and 9 mg of poly(ethylene glycol)-block-
poly(2-methyl-2-carboxyl-propylene carbonate-graft dodecanol) (mPEG-b-PCC-g-
DC) (units of DC is 22) were dissolved in chloroform. Solvent was evaporated 
under vacuum and resulting film was hydrated in 1 mL of PBS followed by 
sonication. Free drug was removed by centrifugation at 3,000 rpm for 5 min and 
filtration using a 0.22 μm filter. To determine the drug loading, PTX or CYP loaded 
micelles were dissolved in methanol and the concentration was measured by 
HPLC. Drug loading was calculated using the following equation:  
Drug loading (w/w %) = Weight of encapsulated drug /Total weight of 
formulation X 100 
2.2.5 In vitro stability of p-ptx and p-cyp micelles 
To determine the stability of P-PTX and P-CYP conjugate micelles under 
the physiological conditions, micelles with final concentration of 1 mg/ml were 
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incubated with 45 mg/mL bovine serum albumin (BSA) at 37 °C with gentle 
agitation. The particle size distribution of these formulations was measured by DLS. 
2.2.6 In vitro drug release 
The release of PTX from P-PTX and CYP from P-CYP was determined at 
pH 5.3 and 7.4 as previously described [55]. Briefly, 1 mg of P-PTX or P-CYP was 
re-suspended in 1 ml buffer solution (0.1 M acetic acetate, pH 5.3 or 0.1 M 
phosphate buffer, pH 7.4) and diluted with methanol in a volume ratio of methanol: 
aqueous solution (1:3, v/v). All samples were incubated at 37 ℃ shaken at 100 rpm 
for 0, 6, 12, 24, 48, 72, 96, 120 and 144 h and neutralized to pH 7.4 prior to HPLC 
analysis  
In vitro release of PTX or CYP from mPEG-b-PCC-g-DC was determined 
by dialysis (7K MWCO) against 50 mL PBS containing 2% Tween 80 at pH 5.3 
and 7.4 with gentle agitation. 1 mL samples were taken at regular time intervals 
and replaced with fresh media. Drug concentration was measured by HPLC as 
described for drug loading. (Waters HPLC system with 996 photodiode array 
detector (Milford, MA, USA)). All experiments were performed in triplicate and the 
data reported as the mean of three individual experiments. Micelles (final 
concentration of 1 mg/ml) were incubated with 45 mg/mL bovine serum albumin 
(BSA) at 37 °C with gentle agitation. HPLC conditions for PTX detection:  column: 
Inertsil®ODS-3 (4.6 × 250 mm; 5 μm), mobile phase: 60:40 acetonitrile: water, 
wavelength: 227 nm. HPLC conditions for CYP detection: column: 
SymmetryShieldTM RP18 (4.6 x 250 mm; 5 μm), mobile phase: 30:70 acetonitrile: 
water (0.1% trifluoroacetic acid); wavelength: 210 nm. 
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2.2.7 Cell culture  
The human metastatic prostate cancer cell lines DU145 and PC3 and their 
PTX resistant versions DU145-TXR and PC3-TXR were a kind gift of Prof. Evan T. 
Keller of the University of Michigan. DU145-TXR cells were cultured in DMEM 
medium supplemented with 10% FBS and 1% penicillin/streptomycin. PC3-TXR 
and PC3-luc-GFP cells were cultured in F-12K medium supplemented with 10% 
FBS and 1% penicillin/streptomycin. All cell lines were grown and maintained in a 
humidified incubator containing 5% CO2 at 37°C. 
2.2.8 Cellular uptake of P-PTX 
To determine the cellular uptake of polymer-drug conjugates, we 
conjugated a fluorescent taxol derivative flutax-1 and dodecanol to copolymer 
mPEG-b-PCC, treated PC3-TXR cells with 0.5 µM of this conjugate (P-flutax-1) for 
12 h and the cellular internalization was observed under a fluorescent microscope 
(Axio Vert.A1, Zeiss, USA) after washing the cells with PBS.  
2.2.9 Cytotoxicity assay  
DU145-TXR and PC3-TXR cells were used to determine the cell growth 
inhibition ability of polymer-drug conjugates. Cells (5X103/well) were seeded in 96-
well plates and 0.5 µM P-PTX, 10 µM P-CYP and the combination of 0.5 µM P-
PTX and 10 µM P-CYP were added to different groups of wells after 24 h. Cell 
viability was assessed by MTT assay after another one to three-day incubation. 
The absorbance was measured at 560 nm and corrected for the cell debris by 
subtracting absorbance at 630 nm. Cell viability was calculated using the following 
formula: 
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Cell viability (%) =Absorbance of test sample/Absorbance of control X 100 
 
2.2.10 Colony formation assay   
PC3-TXR cells were seeded into 6-well plates. Each well had 300 cells and 
treatments of 0.5 µM P-PTX, 10 µM P-CYP and the combination of 0.5 µM P-PTX 
and 10 µM P-CYP were added to the wells after 24 h. At 10 days post incubation, 
colonies in each well were fixed by 10% formalin, stained with 0.5% crystal violet 
solution and visualized under microscopy.  
2.2.11 Real time RT-PCR of microRNA quantification 
DU145-TXR and PC3-TXR cells were treated with 0.5 µM P-PTX, 10 µM P-
CYP and the mixture of 0.5 µM P-PTX, 10 µM P-CYP. After 72 h treatment, total 
RNA was isolated from untreated and drug-treated cancer cells using miRNEasy 
RNA isolation kit (Qiagen, Germany) following manufacturer’s instructions. Then, 
200 ng of total RNA was converted to cDNA using miScript II RT Kit (Qiagen, 
Germany). Diluted cDNA was mixed with universal primer and SYBR Green dye 
and added to the wells of 96-well plates containing miScript primer. The plates 
were run on a Roche Light Cycler 480® instrument and the expression of individual 
miRNAs was analyzed using the obtained Ct values. For each of the selected 
miRNA, a miScript PCR primer was purchased from Qiagen. This assay targets 
only mature miRNAs, not their precursors. Untreated DU145-TXR and PC3-TXR 
were used as the control to calculate the fold change in drug-treated cells, 
respectively. As a normalizer, RNU6-1 was used as a housekeeping miRNA. The 
following miRNA primers were used:  
hsa-miR-29b-3p: UAGCACCAUUUGAAAUCAGUGUU 
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hsa-miR-34a-5p: UGGCAGUGUCUUAGCUGGUUGU 
hsa-miR-148a-3p: UCAGUGCACUACAGAACUUUGU 
hsa-miR-200c-3p: UAAUACUGCCGGGUAAUGAUGGA 
RNU6-1: 
GUGCUCGCUUCGGCAGCACAUAUACUAAAAUUGGAACGAUACAGAGAAGA
UUAGCAUGGCCCCUGCGCAAGGAUGACACGCAAAUUCGUGAAGCGUUCC
AUAUUUU 
2.2.12 Expression of miRNA target genes  
We also determined the levels of several miRNA target genes, such as Gli1, 
PTCH1, ZEB1, ZEB2, E-CAD, CD133 and NOTCH2 at 72 h post treatment of 
DU145-TXR and PC3-TXR cells with the 0.5 µM P-PTX and 10 µM P-CYP. Then 
total RNA were extracted using RNeasy RNA isolation kit (Qiagen, Germany), 
reverse transcribed into cDNA template and amplified by real time RT-PCR using 
SYBR Green dye universal master mix and the primers for different genes. GAPDH 
was used as a housekeeping gene. The following primers were used:   
CD133 forward primer: 5’AAGCATTGGCATCTTCTATGG-3’ 
CD133 reverse primer: 5’-AAGCACAGAGGGTCATTGAGA-3’ 
NOTCH2 forward primer: 5’-GGCATTAATCGCTACAGTTGTGTCT-3’ 
NOTCH2 reverse primer: 5’-GGAGGCACACTCATCAATGTCA-3’ 
Gli1 forward primer: 5’-TCCTACGGTCATCTCTCCATT-3’ 
Gli1 reverse primer: 5’-GCCAGGGAGCTTACATACATAC-3’  
PTCH1 forward primer: 5’-TTGCTTGGGAGTCATTAACTG-3’ 
PTCH1 reverse primer: 5’-CCCACAATCAACTCCTCCTGCC-3’ 
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E-CAD forward primer: 5’-AAGAAGCTGGCTGACATGTACGGA-3’ 
E-CAD reverse primer: 5’-CCACCAGCAACGTGATTTCTGCAT-3’ 
ZEB1 forward primer: 5’-ATGCACAACCAAGTGCAGAAGAGC-3’ 
ZEB1 reverse primer: 5’-TTGCCTGGTTCAGGAGAAGATGGT-3’ 
ZEB2 forward primer: 5’-CTAACCCAAGGAGCAGGTAATC-3’ 
ZEB2 reverse primer: 5’-GGGAAGAACCCGTCTTGATATT-3’ 
GAPDH forward primer: 5’-GATTCCACCCATGGCAAATTC-3’ 
GAPDH reverse primer: 5’-GTCATGAGTCCTTCCACGATAC-3’ 
2.2.13 Evaluation in orthotopic prostate cancer bearing athymic nude mice 
All animal experiments were performed in accordance with the NIH animal 
use guidelines and protocol approved by the Institutional Animal Care and Use 
Committee (IACUC) at the University of Nebraska Medical Center (UNMC), 
Omaha, NE. Orthotopic prostate tumors were established in 8 week-old male 
athymic nude mice by injecting 1 × 10
6 PC3-luc-GFP cells suspended in 50 μl PBS 
into dorsum of the prostate gland. Animals were randomly divided into four groups 
of five animals per group when the radiance of tumor volume had reached 107. 
Formulations were administered to these mice via the tail vein thrice a week for 
two weeks. Group 1 was kept as the control and received normal saline, group 2 
received 10 mg/kg P-PTX PBS solution (equivalent to free PTX), group 3 received 
10 mg/kg P-CYP PBS solution (equivalent to free CYP) and group 4 received the 
mixture of 10mg/kg P-PTX and 10mg/kg P-CYP PBS solution. Bioluminescent 
radiance of tumor was measured every alternate day using IVIS® Spectrum 
imaging system (PerkinElmer Inc., MA). Body weight of these mice was recorded 
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every alternate day. At the end of the animal study (i.e., day 24), mice were 
sacrificed and tumors as well as vital organs (liver, spleen, kidney and heart) were 
excised.  
Five representative tumor tissues were collected per experimental group 
and fixed with 10% buffered formalin for 24h. The fixed samples were embedded 
in paraffin and thin sections of 4 μm were obtained and immunostained for cell 
proliferation marker (Ki-67) and hematoxylin and eosin (H&E). To identify apoptotic 
cells by fluorescein-12−dUTP labeling of fragmented DNA, DeadEnd fluorometric 
TUNEL assay kit was used according to the manufacturer’s instructions. Tumor 
sections were also counterstained with propidium iodide (PI) and imaged under a 
fluorescence microscope. 
2.2.14 Statistical analysis 
Data are represented as means ± SEM. The statistical comparisons of the 
experiments were performed by two-tailed Student’s test. P <0.05 was considered 
statistically significant. 
2.3 RESULTS 
2.3.1 Synthesis and characterization of P-PTX and P-CYP 
P-PTX was synthesized by direct carbodiimide coupling of PTX onto the 
pendant carboxylic acid groups on the hydrophobic block of mPEG-b-PCC 
copolymer and esterification took place preferentially at the 2’-hydroxyl group due 
to its less steric hindrance. In 1H NMR spectra of mPEG-b-PCC, protons 
corresponding to −CH2−CH2−O− of PEG were observed at δ 3.4−3.6, and −CH2− 
units of PCC δ 4.2−4.4 and −COOH were observed at δ 12−14 as reported earlier 
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by our group. After conjugation of PTX to mPEG-b-PCC, protons corresponding to 
PTX were all observed in 1H NMR spectra and PTX content in the conjugates was 
determined to be 25.4±3.7% (w/w), as calculated from the peak intensities of all 
phenyl proton signals from 7.3 to 8.4 ppm. 
1H NMR (500 MHz, DMSO-d6) spectra of mPEG-b-PCC-g-PTX-g-DC 
showed peaks corresponding to PEG (−CH2−CH2−O) at δ3.5, PCC (−CO-O-CH2- 
& CH3-C(CO)-CH2) at δ4.2 (m, 4H), CH3-(CH2)9- at δ0.9 (t, 3H), CH3-(CH2)9- at 
δ1.2-1.45 (bs, 18H), CH3-(CH2)9-CH2 at δ1.5-1.8 (m, 4H), CH3-(CH2)9-CH2-CH2- at 
δ4.02 (m, 2H), PTX-(CH3)2-C6H3 at δ 1.01 (t, 6H), PTX-C6H5-CH3 at δ 1.2 (t, 3H), 
PTX-CH3-C6H3- at δ 1.8 (t, 3H), PTX-CH3-CO-O- at δ 2.3 (t, 3H), PTX-C6H5-CH-
NH- at δ4.78 (m, 1H), PTX-C6H5-CO-O-CH- at δ 4.79 (m, 1H), PTX-CHC2H2O- at 
δ 5.34 (m, 2H), PTX-CH3-CO-O-CH- at δ 6.31 (m, 1H), PTX-C6H5- at δ7.3-8.4 (m, 
15H), PTX-C6H5-CO-NH- at δ 9.0(m, 1H)  (Figure 2A). 
We have tried to conjugate CYP directly onto mPEG-b-PCC but we failed 
to form amide bond between secondary amine of CYP and carboxyl group of 
mPEG-b-PCC (data not shown). Therefore, CYP was conjugated onto mPEG-b-
PCC through a Boc-b-Ala linker because the secondary amine on CYP was not 
easy to conjugate with carboxylic acid group on mPEG-b-PCC, thus after Boc-
removal the primary amine on the linker made the conjugation of CYP to the 
copolymer much easier. After conjugation of CYP to mPEG-b-PCC, protons 
corresponding to CYP were observed in 1H NMR spectra and CYP content in the 
conjugates were 14.5±1.6% (w/w) calculated from proton signal 1.7-2.4 ppm. 
19 
 
1H NMR (500 MHz, DMSO-d6) spectra of mPEG-b-PCC-g-CYP-g-DC 
showed peaks corresponding to CYP-CH3-C4H3O-, CYP-CH3-C5H7N-, CYP-CH3-
C6H5- at δ1.01-1.3 (m, 9H), CYP-CH3-C-CH-CH-CH- at δ1.48-1.88 (m, 3H), CYP-
CH2-CH=C-CH2- at δ1.94-2.21 (m, 4H), CYP-O-C-CH-CH3 at δ 2.50 (m, 1H), CYP-
CH3-CH-CH2-N-CO-CH2- at δ 2.46 (m, 2H), CYP-CH3-CH-CH2-N-CO- at δ 3.68, 
CYP-CH3-CH-CH2-N-CH- at δ 3.75 (m, 1H), CYP-CH3-C-CO-NH-CH2- at δ 8.01 
(m, 1H) (Figure 2B). 
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Figure 2. 1H NMR spectra of two polymer-drug conjugates. (A) P-PTX, (B) 
P-CYP. 
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2.3.2 Formulation characterization 
High drug payload of these polymer-drug conjugates was observed by using 
1H NMR characterization (Figure 2):  25.40±3.70% (w/w) and 14.50±1.60% (w/w) 
for PTX and CYP, respectively. Unlike polymer-drug conjugates, PTX and CYP 
loadings in physically encapsulated micelles were 8.21±0.01% (w/w) and 
5.36±0.07% (w/w), respectively.  
P-PTX and P-CYP conjugate micelles were prepared by dissolving 10 mg 
of P-PTX or P-CYP in dichloromethane followed by solvent evaporation under 
reduced pressure to form a thin film, followed by hydration with 1 mL of PBS (pH 
7.4). The mean particle sizes of P-PTX and P-CYP were 70.02 ± 0.22 nm (PDI 
0.223) and 76.37 ± 0.15 nm (PDI 0.273), respectively. CMC values were 3 × 10−4 
g/L for P-PTX and 4 × 10−4 g/L for P-CYP.   
2.3.3 In vitro stability of P-PTX and P-CYP micelles  
Within 48 hours, there was no significant change in the mean particle size 
of P-PTX and P-CYP micelles before and after their incubation with BSA, 
suggesting that plasma proteins were unlikely to affect the integrity of these 
polymer-drug conjugate micelles (Figure 3). 
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2.3.4 PH dependent drug release 
In vitro drug release studies were carried out in PBS buffer with pH 7.4 and 
acetate buffer with pH 5.3 to simulate drug release in blood and tumor cells. P-
PTX or P-CYP showed a slow but sustained release of PTX and CYP, respectively. 
Due to the stability of conjugated PTX and CYP, there was no noticeable initial 
burst release of these drugs at different pH 7.4 and 5.3. At neutral environment, 
both ester and amide bonds were stable and no significant release of PTX and 
CYP was observed. Since the liberation of free drugs required pH-dependent 
cleavage of ester and amide linkages, the percentage of PTX and CYP released 
from the conjugated micelles significantly increased as pH was decreased from 
7.4 to 5.3. After six days, more than 25% of PTX and CYP was observed at pH 5.3, 
while about 10% of PTX and CYP was released at pH 7.4 (Figure 4A).  
 
 
Figure 3. In vitro stability of P-PTX and P-CYP micelles in BSA after 12h, 24h 
and 48h. (A) P-PTX, (B) P-CYP. 
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To better confirm the advantages of drug-conjugated micelles, we also 
determined the release of PTX and CYP from physical-encapsulated micelles. As 
expected, both PTX and CYP were released very fast. In the first 12 hours, burst 
release of two drugs was observed and almost 60% of drugs were released after 
24 hours (Figure 5). In addition, with incubation of BSA both PTX and CYP were 
released from the conjugates very slowly as determined by HPLC (Figure 4B). 
The mean particle sizes of P-PTX and P-CYP micelles before and after their 
incubation with BSA were also monitored by DLS but there was no significant 
change during 48 h (Figure 3). These results suggested that the conjugated 
micelles were stable under physiologically simulating conditions.  
 
 
Figure 4. In vitro release of PTX from P-PTX and CYP from P-CYP at different 
pH and with incubation of BSA. Drug concentrations from each time point were 
measured by HPLC and drug release profiles were represented as the mean± SEM. 
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2.3.5 Cellular internalization 
P-flutax-1 conjugate was efficiently taken up by the cells as evidenced by 
green fluorescent positive cells (Figure 6).  
   
 
Figure 5. In vitro release of PTX and CYP from physically drug encapsulated 
micelles at pH 7.4 and 5.3. (A) PTX, (B) CYP. Drug concentrations from each time 
point were measured by HPLC and drug release profiles were represented as the 
mean± SEM. 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 6. Intracellular accumulation of P-flutax-1. PC3-TXR cells were incubated 
with 0.5 µM P-flutax-1 for 12 h, and the intracellular accumulation of P-flutax-1 was 
observed by Axio Vert.A1 Microscope. 
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2.3.6 Cytotoxicity and colony formation assays 
Cytotoxicity of 0.5 µM P-PTX, 10 µM P-CYP and the combination of 0.5 µM 
P-PTX and 10 µM P-CYP was determined by incubating DU145-TXR and PC3-
TXR cells with these polymer-drug conjugate micelles for 24, 48 and 72 h. Due to 
the slow release of these drugs from the polymer conjugates, combination therapy 
of P-PTX and P-CYP had the highest cell-killing effect at 72 h compared to 24 or 
48 h post incubation. Treatment with the combination formulation after 72 h killed 
45.6% of DU145-TXR cells and 47.1% of PC3-TXR (Figure 7A-B).  Both P-PTX 
and P-CYP monotherapy failed to kill many cells at those doses, suggesting that 
the combination formulation was quite effective in killing chemoresistant cancer 
cells.  
Tumorigenic potential of PC3-TXR cells was determined by colony 
formation assay after treatment with P-PTX, P-CYP and their combination. Due to 
the long-term treatment of polymer-drug conjugates, a large % of PTX and CYP 
was released from the conjugates, resulting in significant anti-proliferative effect. 
The number of colonies formed from untreated group was largest compared with  
0.5 µM P-PTX, 10 µM P-CYP or the combination treated group, and the number 
of colonies formed from combination treated group was significantly less compared 
with other three groups (Figure 7C-D).   
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2.3.7 Effect of combination therapy on miRNAs and their target genes 
The effect of 10 µM P-CYP and its combination with 0.5 µM P-PTX on the 
expression of miR-29b, miR-34a, miR-148a and miR-200c was determined in 
DU145-TXR and PC3-TXR cells using real time RT-PCR. All these tumor 
suppressor miRNAs were upregulated when treated with either 10 µM P-CYP or 
its combination with 0.5 µM P-PTX (Figure 8). However, this effect was better 
when the cells were treated with the combination therapy. 
We also determined the levels of several known downstream targets of 
these miRNAs and Hh signaling. There was downregulation of miR-200c target 
 
Figure 7.  Cytotoxicity and colony formation assay. Cytotoxicity assay of 0.5μM 
P-PTX, 10µM P-CYP and their combination was determined in DU145-TXR and 
PC3-TXR cells for 24, 48 and 72 h (A-B). For colony formation assay, 300 PC3-TXR 
cells per well were seeded to 6-well culture plates. At 24h, drug formulations were 
added and at 10 days, cell colonies were fixed, stained and counted *p<0.05, 
**p<0.01 vs P-PTX+P-CYP (C-D). 
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genes like ZEB-1 by 1.30 fold in PC3-TXR cells and ZEB-2 by 2.32 fold in DU145-
TXR cells, while the expression of another miR-200c target E-CAD was 
upregulated in DU145-TXR cells by 4.75 fold and PC3-TXR cells by 3.62 fold 
(Figure 8). miR-34a target gene CD133 was significantly downregulated and 
NOTCH2 which is the target gene of miR-29b was also downregulated in DU145-
TXR cells by 2.0 fold and PC3-TXR cells by 7.69 fold. In addition, gene targets of 
Hh signaling such as Gli1 and PTCH1 were regulated in a reverse pattern. While 
Gli1 was highly downregulated in PC3-TXR after combination therapy, PTCH1 was 
upregulated in DU145-TXR cells by 3.22 fold and PC3-TXR cells by 1.89 fold 
indicating Hh signaling was inhibited when these cells were treated with the 
mixture of P-PTX and P-CYP.  
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2.3.8 Efficacy in orthotopic prostate tumor bearing mice  
We established orthotopic prostate tumor in 8 weeks old male athymic nude 
mice by injecting 1x106 PC3-luc-GFP cells. At day 7, all mice were imaged for 
 
 
Figure 8. Effect of combination therapy on tumor suppressor miRNA expression 
and their target genes. DU145-TXR (A) and PC3-TXR (B) cells were used. To 
determine miRNA expression, cells were treated with 10 µM P-CYP or  combination 
of 0.5µM P-PTX and 10µM P-CYP for 72 h. Total RNA was extracted using miRNEasy 
RNA isolation kit, converted to cDNA and used for miScript primer assay for 
determining miR-29b, miR-34a, miR-148a and miR-200c expression. Untreated cells 
were used as the control for calculating fold change. RNU6-1 was used as a 
housekeeping miRNA. To determine gene expression, cells were treated with 
combination of 0.5µM P-PTX and 10µM P-CYP for 72 h. Following RNA extraction and 
SYBR Green based real time RT-PCR using specific gene primers, Ct values were 
calculated. Untreated cells were used to normalize gene expression and GAPDH was 
used as a housekeeping gene. 
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luciferase bioluminescence to determine the tumor growth rate (Figure 9) and 
mice whose bioluminescent radiance achieved 107 were randomized into four 
groups: i) control, ii) P-PTX, iii) P-CYP and iv) combination of P-PTX and P-CYP.  
 
These polymer-drug conjugates were administered intravenously thrice a 
week for two weeks at equivalent doses of 10 mg/kg PTX and 10 mg/kg CYP. All 
the treatment groups had significantly lower tumor growth compared with the 
control group. However, a significantly higher tumor growth inhibition was 
observed in the group treated with the combination therapy compared with the 
formulations containing either P-PTX or P-CYP (Figure 10A-B). 
 
 
Figure 9. In vivo representative bioluminescent images at day 7 and day 24. 
Mice (n=5) from control (saline), P-PTX, P-CYP and P-PTX+P-CYP group were taken 
bioluminescent images every alternative day from day 7 to day 24.  
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The body weights of the mice did not drop after systemic administration of 
saline or polymer-drug conjugates, with steady increase at similar rates in all 
groups (Figure 10C). This indicates that P–PTX, P–CYP and their combination 
are well tolerated. In addition, the chronic toxicities of these formulations were also 
evaluated by histological analysis of the major organs (Figure 11). No obvious 
histological changes were observed in the livers, spleens, kidneys and hearts from 
 
Figure 10. In vivo efficacy of P-PTX and P-CYP after systemic administration in 
PC-3 orthotopic prostate cancer bearing athymic nude mice. Mice (n=5) received 
10 mg/kg P-PTX, 10 mg/kg P-CYP either alone or in combination at day 7 after tumor 
implantation. A) Radiance intensity plot of all groups were measured from day 7 to 
day 24. Data represented as the mean ± SEM, B) Representative tumors of each 
group were excised after sacrificing the mice at the end of the experiment, C) Body 
weight of each group. 
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all the treatment groups.  
 
Immunohistochemical analysis showed tumor sections from P-PTX, P-CYP 
and combination of P-PTX with P-CYP treated group had significant necrotic area 
with less number of live tumor cells, whereas control tumor remained viable. 
Notably, the combination therapy showed more necrotic areas compared with 
monotherapy. Furthermore, mice treated with the combination therapy showed 
least Ki-67 staining compared with P-PTX, P-CYP and control treated groups 
(Figure 12A).  In TUNEL assay, control group did not have much TUNEL-positive 
 
Figure 11. Hematoxylin and Eosin (H&E) staining of major organs (liver, spleen, 
kidney and heart). Organ samples from control (saline), P-PTX, P-CYP and P-PTX + 
P-CYP treated groups were excised, fixed and stained for H&E. 
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green fluorescent cells while P-PTX or P-CYP treated group showed modest 
increase in the number of apoptotic cells. The combination of P-PTX and P-CYP 
showed significantly enhanced apoptosis supporting the tumor growth inhibition 
potential of this combination therapy (Figure 12B). 
 
 
 
Figure 12. Analysis of tumor samples for hematoxylin and eosin (H&E) and Ki-
67 (cell proliferation marker) staining and TUNEL assay. Control (Saline), P-PTX, 
P-CYP and P-PTX + P-CYP treated tumor samples were excised, fixed and 
immunostained for H&E and Ki-67 (A), and stained for TUNEL-positive nuclei (green) 
and propidium iodide (red) positive nuclei (B). 
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2.4 DISCUSSION 
HRPC poses a medical challenge due to its insensitivity to the majority of 
chemotherapeutic agents after long-term treatment. Emerging therapies directed 
against different pathways include mTOR, MAPK/ERK, NFκB/IL-6, endothelin A 
receptor, and somatostatin receptor [56]. While these therapies have 
partially restored the sensitivity of prostate tumors to taxanes like PTX and DTX, 
the benefit was only moderate or little compared to monotherapy. 
Supplementation of Hh signaling inhibitor to chemotherapy has the potential 
to eliminate the chemoresistance in advanced prostate cancer and to improve the 
therapeutic efficacy of PTX by targeting both bulk tumor cells and CSCs, and 
restoring the expression of dysregulated miRNA. Emerging evidence suggests that 
numerous dysregulated miRNAs are implicated in the pathogenesis of prostate 
cancer. Since expression profiles of miRNAs in tumors are tissue-specific [57], 
miRNA could be not only an ideal class of biomarkers for cancer detection, but 
also promising targets for cancer therapy. Therefore, CYP as an Hh signaling 
inhibitor will augment PTX therapy by restoring the expression of tumor suppressor 
miRNAs and thereby would improve the overall efficacy of chemotherapy.  
For improved clinical translation of the combination therapy with reduced 
toxicity and better safety, we conjugated PTX and CYP to a biodegradable 
amphiphilic diblock copolymer mPEG-b-PCC with pendant carboxyl acid groups. 
We have previously conjugated a water soluble drug gemcitabine as well as 
dodecanol to mPEG-b-PCC. This polymer-drug conjugate self-assembled into 
micelles and showed enhanced stability and antitumor effect of gemcitabine [58]. 
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In this study, PTX was conjugated to mPEG-b-PCC through an ester bond at its 
2’-OH position which is more active than other two hydroxyl groups. For binding 
CYP to mPEG-b-PCC we used a linker containing thiazolidine-2-thione to react 
with secondary amine in CYP (Figure 1). Additionally, the attachment of DC 
enhanced requisite hydrophobicity and assisted in the self-assembling of polymer-
drug-conjugate micelles. These polymer-drug conjugates were characterized by 
1H NMR (Figure 2). Therefore, this conjugation strategy imparted high payload of 
PTX (25.4±3.7%) and CYP (14.5±1.6%) and small micellar sizes of 70-76 nm. 
Since the preparation of physical encapsulation of drugs into micelles is easier 
compared to polymer-drug conjugation, we also physically encapsulated PTX and 
CYP into mPEG-b-PCC-g-DC by film hydration. As expected, drug loading in these 
physically drug encapsulated micelles was 8.21±0.01% for PTX and 5.36±0.07% 
for CYP.  
Physically encapsulated drugs into polymeric micelles are usually released 
fast, with burst release due to the dynamic instability of micelles. This means 
higher initial drug loading is needed because drugs should ideally be released at 
the disease site to reduce their adverse effects. In contrast, chemical conjugation 
of drugs to amphiphilic polymers via ester, amide, and disulfide bonds prevents 
immediate drug release during the transport of polymer-drug conjugates and 
provides long-term sustained release of drugs. Therefore, polymer-drug 
conjugation prolongs drug circulation and therapeutic efficacy. To confirm the 
different drug-release profiles between chemical conjugation and physical 
encapsulation we also determined the release of PTX and CYP from physically 
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drug encapsulated micelles. As expected, both PTX and CYP were released very 
fast, with the burst release of these two drugs in the first 12 h and almost 60% 
release at 24 hours (Figure 5), which is in good agreement with the literature 
[59,60]. In contrast, PTX and CYP were released from conjugated micelles at a 
slow but appreciable rate, which suggested that these polymer-drug conjugate 
micelles could prolong the circulation of PTX and CYP. The percentage of PTX 
and CYP released from significantly increased as pH was decreased from 7.4 to 
5.3. However, even after six days, only about 25% of PTX and CYP were released 
at pH 5.3, but only 10% of PTX and CYP were released at pH 7.4 (Figure 4A).   
So far polymer-drug conjugates with linear backbone have undergone 
clinical evaluation, such as polyethyleneglycol (PEG), poly[N-(2-
hydroxypropyl)methacrylamide] (PHPMA) copolymers, dextran and poly(glutamic 
acid) (PGA) and they display numerous features and advantages among all nano-
sized carriers for cancer therapy [61-63]. Our polymer-drug conjugate micelles 
offer distinct advantages in terms of a) PEG corona on the polymer imparts stealth 
property; b) conjugation ensures in vivo stability and no premature drug release in 
the circulation; c) small size of these micelles can take advantage of the EPR effect 
to maximize drug delivery to prostate tumor. 
We previously demonstrated that CYP could target CSCs derived from 
PTX-resistant prostate cancer cell lines DU145-TXR and PC3-TXR and 
combination therapy of PTX and CYP could reverse PTX chemoresistance and 
eliminate CSC fraction in chemoresistant prostate cancer cells [64]. Therefore, in 
this study we evaluated the inhibitory effect of P-PTX and P-CYP on DU145-TXR 
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and PC3-TXR cells. We first determined cellular uptake of the conjugates. PTX 
was replaced by a fluorescent taxol derivative flutax-1 which was conjugated to 
mPEG-b-PCC along with dodecanol to obtain P-flutax-1. Green-fluorescent 
positive PC3-TXR cells confirmed the successful cellular internalization of the 
conjugates (Figure 6). In followed cytotoxicity assay P-PTX with 0.5 μM equivalent 
PTX was not able to kill many cells due to the development of resistance to PTX. 
However, the treatment with the combination of 0.5 μM PTX and 10 μM P-CYP for 
72 hours killed almost half of the cells (Figure 7), which is in good agreement with 
our previous observation [64]. This further suggests that this combination therapy 
had potentials to treat chemoresistant prostate cancer.  
Treatment of DU145-TXR and PC3-TXR cells with 10 µM P-CYP alone  or 
in combination with 0.5 µM P-PTX resulted in upregulation of tumor suppressor 
miRNAs like miR-29b, miR-34a, miR-148a and miR-200c (Figure 8), leading to 
increase in chemosensitivity to PTX.  Emerging evidence demonstrates that miR-
200c, a member of miR-200 family, is one of the essential regulators of 
chemoresistance as well as epithelial-mesenchymal transition (EMT). Expression 
level of miR-200c is significantly downregulated in DTX-resistant prostate cancer 
cells compared with non-resistant cells and restoration of miR-200c results in 
apoptosis of DTX–resistant cells and reversal of EMT [65]. As tumor suppressor 
miRNA, miR-34a not only has strong inhibitory effects of prostate cancer but also 
can negatively affect prostate CSCs on the tumor-initiating ability and inhibit their 
CSC properties such as sphere formation and clonogenic capacity [66]. miR-29b 
can repress expression of Hh pathway and the inhibition of this signaling leads to 
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the restoration of miR-29b expression [45,67,68]. miR-148a is reported to inhibit 
the proliferation and metastasis of PTX-resistant prostate cancer and also 
attenuate the resistance to PTX [69]. Based on these evidences and combining 
our results, we confirmed that chemoresistance to PTX could be due to the altered 
miRNA expression. Therefore, the combination of P-PTX and P-CYP could 
alleviate chemoresistance by targeting miRNAs participated in chemoresistance. 
In vivo efficacy of P-PTX and P-CYP conjugate micelles was determined in 
orthotopic tumor model developed by PC3-luc-GFP cells in athymic nude mice. 
Promising results were obtained in three treated groups wherein the combination 
therapy of P-PTX and P-CYP resulted in a significant reduction in tumor growth 
rate and tumor size compared with the control group (Figure 10). In addition, the 
significantly low level of cellular proliferation and high level of apoptotic cells found 
in combination group demonstrated combined P-PTX and P-CYP reduces tumor 
growth synergistically (Figure 12). Furthermore, our formulation carrying P-PTX 
and P-CYP conjugate micelles were well tolerated as the vital organs such as livers, 
spleens, kidneys and hearts did not show any histological changes after treatments 
(Figure 11). These results are in good agreement with the work of Kopecek and 
associates who demonstrated that the combination of HPMA-CYP and HPMA-
DTX conjugates significantly inhibited prostate tumor growth [70]. Unlike our 
current studies these authors used subcutaneous tumor model, while we have 
evaluated our formulations in orthotopic prostate tumor model. 
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CHAPTER 3 POLYMERIC MICELLAR DELIVERY OF NOVEL 
MICROTUBULE DESTABILIZER AND HEDGEHOG SIGNALING 
INHIBITOR FOR SYNERGISTICALLY TREATING 
CHEMORESISTANT PROSTATE CANCER 
3.1 INTRODUCTION 
Prostate cancer (PCa) is the most common non-cutaneous malignancy and 
the second leading cause of cancer related mortality in American men. PCa at 
stage I/II can be treated by surgery or radiation therapy but if the cancer has grown 
outside the prostate or come back after surgery or radiation, androgen deprivation 
therapy may be used to reduce androgen levels. Unfortunately, after a certain 
period the aggressive portion of prostate cancer cells develops resistance to 
hormone treatment and become androgen independent. Alternatively, 
chemotherapy is given along with hormone therapy to enhance therapeutic 
efficacy. Docetaxel (Taxotere®) is a clinically approved drug to treat castration-
resistant prostate cancer including metastatic prostate cancers and it has been 
proven to provide a modest survival benefit for patients with advanced prostate 
cancers. However, a potential challenge of using docetaxel or paclitaxel as cancer 
treatment in the long term is that their anticancer activities could be hindered by 
intrinsic or acquired drug resistance due to mutation of β-tubulin, affected 
androgen receptor signaling or overexpression of drug efflux pumps (ATP-binding 
cassette) in cancer cells [71-74]. Therefore, there is an urgent need to identify 
novel therapeutic agents for treating docetaxel-resistant patients. 
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A number of agents targeting colchicine binding cite of tubulin have been 
reported to effectively inhibit tumors that are resistant to taxanes and vinca 
alkaloids, suggesting that this type of tubulin inhibitors can circumvent the 
limitations associated with clinically available tubulin inhibitors [75,76]. Previously, 
we have synthesized and evaluated a series of novel microtubule destabilizers [77-
81], which can target colchicine domain of tubulin and interfere with tubulin 
polymerization. Although these new compounds have shown potent anticancer 
activity, tumor heterogeneity and the complexity of cell signaling pathways in tumor 
microenvironment make curing cancer through monotherapy a formidable 
challenge. Combination chemotherapy using two or more anticancer agents that 
work together synergistically by different mechanisms of action can increase the 
chance of long-term remission and prevent potential drug resistance. Hedgehog 
(Hh) signaling participates in the initiation and progression of various cancers, thus 
its aberrant activation is considered as a hallmark of cancers. Importantly, Hh 
signaling is needed for regeneration of prostate epithelium through crosstalk with 
androgen signaling, suggesting that inhibition of Hh pathway has the possibility to 
induce anti-proliferative and apoptotic effect on prostate cancer cells [38,39,82,83]. 
Furthermore, Hh signaling involves in the initiation and maintenance of cancer 
stem cells (CSCs), a subset of cancer cells with self-renewal and tumorigenic 
potentials, which have been demonstrated to play key roles in chemoresistance, 
metastatic progression and epithelial-mesenchymal transition [40-42]. In our 
previous studies [64,84], we also have proved the significant benefit using 
combination of Hh signaling inhibitor cyclopamine and paclitaxel to combat taxane-
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resistant prostate cancer cells in vitro and vivo. Recently, our group developed a 
series of analogs of GDC-0449, a FDA-approved Hh pathway inhibitor, and one of 
the analogs, MDB5, exhibited stronger inhibition to Hh pathway and anticancer 
effect in vitro and vivo than GDC-0449 [85]. Therefore, in the current study we 
propose that the new combination therapy of a novel microtubule destabilizer and 
a novel Hh inhibitor can work synergistically through different mechanisms to treat 
taxane-resistant prostate (Figure 13), as the microtubule destabilizer can kill bulk 
tumor cells and the Hh inhibitor can suppress Hh signaling and the proliferation of 
CSCs resulting in alleviation of chemoresistance.  
 
In further, considering the hydrophobicity of the two novel agents requiring 
an appropriate drug delivery carrier, we synthesized a diblock copolymer 
poly(ethylene glycol)-block-poly(trimethylene carbonate-co-2-methyl-2-
 
              
 
Figure 13. Structures of QW-296 and MDB5. 
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benzoxycarbonyl-propylene carbonate) (abbreviated as mPEG-p(TMC-MBC)) via 
ring-opening polymerization and prepared polymeric nanoparticles to physically 
encapsulate two small molecules leading to enhanced water solubility, prolonged 
circulation and reduced side effects. 
To sum up, the anticancer effect and corresponding mechanisms of the 
combination chemotherapy was thoroughly determined by using different prostate 
cancer cells and orthotopic mouse model. It is the first time we introduced a new 
therapeutic strategy to treat taxane-resistant prostate cancer, which would bring 
potential promise to improve current regimens. 
3.2 METHODS 
3.2.1 Materials 
Poly(ethylene glycol) methyl ether (mPEG, Mn=5000, PDI=1.03) was dried 
by anzeotropical distillation form anhydrous toluene just before use. Trimethylene 
carbonate (TMC) was obtained from Polysciences. Anhydrous chloroform, 
dichloromethane (DCM), toluene, stannous 2-ethylhexanoate (Sn(Oct)2), and 
diethyl ether were available commercially from Aldrich and used as received. 
Deuterated chloroform (CDCl3) was purchased from Cambridge Isotope 
Laboratories. Other chemicals were all of analytic grade and were used without 
further purification.  
3.2.2 Cell culture 
Human prostate cancer cell lines with taxane resistance DU145-TXR and 
PC3-TXR were kindly provided by Dr. Evan T. Keller from University of Michigan. 
The cells were cultured in RPMI1640 medium supplemented with 10% FBS and 
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1% penicillin/streptomycin in a humidified incubator containing 5% CO2 at 37 °C 
and their resistance to taxane were maintained by adding 200 nM paclitaxel to 
growth media biweekly. 
3.2.3 Cytotoxicity of QW-296 and MDB5 
PC3-TXR and DU145-TXR cells were used to determine the cytotoxicity of 
QW-296, MDB5 or their combination. After attached to the bottom of plate, cells 
were incubated with different concentrations of QW-296, MDB5 or combination for 
another 72 h. Cell viability was then determined by MTT assay and the absorbance 
was measured at 560 nm with subtraction of absorbance at 630 nm. Each group 
was performed in triplicate and the data reported as the mean ± SEM. 
3.2.4 Combination effect and their Interaction analysis 
Chou-Talalay method and CompuSyn software were used to determine 
whether the combination had synergism, additivity, or antagonism [86]. PC3-TXR 
cells were treated with different combinations at a constant molar ratio, and the 
combination index (CI) was then determined by the software. CI values below 0.9, 
between 0.9 and 1.1, or above 1.1 indicate synergism, additivity or antagonism, 
respectively. 
3.2.5 Cell cycle analysis by propidium iodide staining 
PC3-TXR cells were cultured in a 24-well plate and treated with QW-296, 
MDB5 or their combination for 48 h and 72 h. Cells were harvested, fixed in 70% 
ice-cold ethanol for 1 h and washed by PBS. A cell pellet containing 1 × 106 cells 
was then re-suspended in 0.5 mL of FxCycle™ PI/RNase staining solution and 
incubated for 15 min at room temperature. Cell cycle was measured by a flow 
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cytometer (BD FACSCalibur NJ). Results from 20,000 fluorescent events were 
obtained for analysis. 
3.2.6 Colony formation assay 
PC3-TXR cells were seeded at 300 cells/well into 6-well plates and allowed 
to grow for two days. Treatment of QW-296, MDB5 or combination was given to 
different wells. After a 7 day-incubation, colonies in each well were fixed by 10% 
formalin, stained with 0.5% crystal violet solution and visualized under a 
microscope. Each group was performed in triplicate. 
3.2.7 Western blotting  
Protein was isolated from PC3-TXR cells after 72 h treatment of QW-296, 
MDB5 or combination and protein concentration was determined by Micro BCATM 
Protein assay kit (Thermo Fisher Scientific, Waltham, MA). Equal amounts of 
protein (50 µg) were separated in 4–15% Mini PROTEAN® TGXTM Precast Gel 
followed by transferring to polyvinylidenefluoride (PVDF) membranes by iBlot® Gel 
Transfer system (Thermo Fisher Scientific, Waltham, MA). After the membrane 
was blocked by Odyssey® Blocking Buffer (TBS), the following primary antibodies 
were used: Shh (sc-9024), β-actin (sc-47778) (Santa Cruz Biotechnology, Dallas, 
TX.) Subsequently, the membrane was incubated with their corresponding IRDye® 
800CW secondary antibodies and target proteins were detected by Odyssey® CLx 
Imaging System (LI-COR Biosciences, Lincoln, NE). 
3.2.8 Synthesis and characterization of mPEG-poly(TMC-MBC) 
Monomer 5-Methyl-5-benzyloxycarbonyl-1,3-dioxane-2-one (MBC) and the 
copolymer mPEG-poly(TMC-MBC) were synthesized as reported previously with 
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minor modification [87]. In brief, mPEG (1 g, 0.0002 mol), TMC (307 mg, 0.003 
mol) and MBC (750 mg, 0.003mol) were mixed in a dried round bottom flask under 
vacuum, and then Sn(Oct)2 (10 mol% relative to mPEG) as a catalyst was added 
to the mixture to initiate polymerization. The reaction mixture was heated to 120 °C 
for 24 h under stirring. Afterward, the product was dissolved in chloroform and 
precipitated in a large amount of diethyl ether and dried under vacuum. The 
purified copolymer was characterized by 1H NMR and spectrum was recorded on 
a Bruker (500MHz, T=25 °C) using deuterated chloroform (CDCl3) as solvent.  
3.2.9 Preparation and characterization of polymeric micelles 
Polymeric micelles were prepared using thin-film hydration method. Briefly, 
a given amounts of mPEG-p(TMC-MBC) and the anticancer compound (10% w/w 
relative to the copolymer) were dissolved in chloroform in a glass vial and a thin 
film was formed after removing solvent under reduced pressure. The lipid film was 
hydrated by PBS buffer and the micelle solution was formed under ultrasonic bath 
at 37 °C. The formulation was then centrifuged at 3000 rpm for 5 min followed by 
membrane filtration to remove any unformulated drug. The hydrodynamic 
diameters and zeta potentials were measured by a Zetasizer Nano ZS90 (Malvern, 
Worcestershire, UK) at a scattering angle of 90°. Particle size distribution was 
reported as the mean ± SEM. of three independent samples. Critical micelle 
concentration (CMC) was determined using pyrene as a hydrophobic fluorescent 
probe as described previously [87]. 
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3.2.10 Drug loading and encapsulation efficiency 
Briefly, MDB5 and QW-296 loaded micelles were dissolved in acetonitrile 
for drug extraction and drug content was determined by HPLC/UV-Vis analysis 
(Shimadzu, Kyoto Japan) on Phenomenex Aqua C18 column (5µm, 250 mm×4.6 
mm) using acetonitrile and water (55:45, v/v) as mobile phase. Detection 
wavelength of QW-296 and MDB5 were 222 nm and 261 nm, respectively. Payload 
and encapsulation efficiency were calculated using the following equations: 
Drug Loading (
𝑤
𝑤
%) =
amount of extracted drug
total weight of formulation
× 100% 
Encapsulation Efficiency (%) =
amount of extracted drug
initial weight of drug
× 100% 
3.2.11 Drug release from polymeric micelles 
Drug-loaded micelles with a final concentration of 1 mg/mL were placed into 
a dialysis membrane with a molecular weight cut-off of 3500 Da and dialyzed 
against 50 mL buffer solution (0.1 M acetic acetate, pH 6.5 or 0.1 M PBS, pH 7.2) 
with 0.5% Tween-80 in a thermo-controlled shaker with a stirring speed of 100 rpm. 
1 mL samples were withdrawn at specified times for a period of five days and drug 
concentration was analyzed by HPLC. All experiments were performed in triplicate 
and the data reported as the mean of the three individual experiments. 
3.2.12 In vivo study 
All animal experiments were performed in accordance with the NIH animal 
use guideline and protocol approved by the Institutional Animal Care and Use 
Committee (IACUC) at University of Nebraska Medical Center. Orthotopic prostate 
tumors were established in 8-week-old male athymic nude mice by injecting 1.5 × 
46 
 
106 PC3TXR-luc cells suspended in 50 μl PBS into dorsum of the prostate gland. 
Animals were randomly divided into five groups after one week and different 
treatments were administered intravenously every three days for five times. Group 
1 was kept as the control and received normal saline, group 2 received 10 mg/kg 
QW-296 in micelle solution, group 3 received 10 mg/kg MDB5 in micelle solution, 
group 4 received 5 mg/kg QW-296 and 5 mg/kg MDB5 in cosolvent (12% 
Cremophor® EL, 12% ethanol and 76% PBS), and group 5 received 5 mg/kg QW-
296 and 5 mg/kg MDB5 in micelle solution. Body weight of mice was recorded 
twice a week. At the end of the animal study (i.e., day 24), mice were sacrificed 
and tumors as well as vital organs (liver, spleen, kidney and heart) were excised. 
Three representative tumors were collected per group and fixed with 10% buffered 
formalin for 24h. The fixed samples were embedded in paraffin and thin sections 
of 4 μm were obtained and immunostained for hematoxylin and eosin (H&E) and 
cleaved Caspase 3. The side effects of each treatment were evaluated by H&E 
staining of the major organs.  
3.2.13 Statistical analysis 
Data were represented as the mean± SEM. The statistical comparisons of 
the experiments were performed by two-tailed Student's t-test. P﹤0.05 was 
considered statistically significant. 
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3.3 RESULTS 
3.3.1 Better anticancer activity of two novel compounds compared with 
their counterparts 
We firstly confirmed that PC3-TXR and DU145-TXR cells exhibited high 
resistance to docetaxel (Figure 14). In the contrast, QW-296 exhibited strong cell 
killing activity against two taxane-resistant cell lines with IC50 at 80 nM and 100 nM, 
respectively, as shown in Figure 1B. In addition, PC3-TXR cells showed more 
sensitivity to QW-296 than DU145-TXR cells. 
 
We also compared the anticancer effects of MDB5 and GDC-0449 using 
the two cell lines (Figure 15). The results confirmed that both MDB5 and GDC-
0449 suppressed the growth of PC3-TXR and DU145-TXR cells in a dose-
dependent manner, while MDB5 showed significantly enhanced activity with IC50 
 
 
 
Figure 14. Cytotoxicity assay of Docetaxel and QW-296 on PC3-TXR and 
DU145-TXR for 72h. 
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at 40 µM than its parent drug, indicating the expected benefit of developing novel 
analog of GDC-0449.   
 
3.3.2 Synergism of QW-296 and MDB5 against taxane-resistant PCa cells 
After testing cytotoxicity of individual drug, we confirmed the advantages of 
combination therapy with different concentrations (Figure 16). The concentrations 
of QW-296 and MDB5 applied in combination were lower than their IC50 in 
monotherapy, but the results proved combination at low concentrations worked 
efficiently than individual treatment. Combination of QW-296 (25 nM) and MDB5 
(7.5 µM) only killed 20% of PC3-TXR, but when their concentrations were both 
doubled the combination killed 72% of cells. Two different combinations (Q 20 
nM/M 20 µM, or Q 40 nM/M 10 µM) killed 40% of cells, but when the concentration 
of single drug was doubled (Q 40 nM/M 20 µM) the combination killed 70% of cells. 
All the above results suggested the two small molecules worked together not in an 
additive manner and the anticancer effect of their combination could enhance 
significantly at a certain combination ratio. 
 
 
Figure 15. Cytotoxicity assay of MDB5 and GDC-0449. A) PC3-TXR and B) DU145-
TXR for 72h. 
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The interactions between the two drugs were determined by Chou-Talalay 
method and CompuSyn software, and we analyzed their combinations with 
different concentration ratios. The Combination Index (CI) values below 0.9, 
between 0.9 and 1.1, or above 1.1 indicate synergism, additivity or antagonism, 
respectively. The Fa (i.e. fraction affected, degree of growth inhibition) and CI 
values of different combinations were summarized in Figure 16 B-D and Table 1. 
When the combinations inhibited 50% of cells (i.e. Fa=50%), their CI values were 
in the range of additive effect, however, strong synergistic effect (the lower CI, the 
stronger synergism) was observed in three combinations when Fa level ranging 
from 75% to 95%. These results indicated that when concentration of each drug 
was around half of its corresponding IC50 dose, their combination not only resulted 
in high level of growth inhibition (75% or above) but also worked together in the 
trend of synergism. Overall, this preliminary study explained the mechanism 
behind the drug interaction between QW-296 and MDB5 and the benefit of 
combination therapy was approved. 
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Table 1. Combination index of QW-296 and MDB5 with various ratios against PC3-
TXR 
Ratios of Q/M 
Combination index (CI) 
Fa25 Fa50 Fa75 Fa90 
1:200 1.81 0.92 0.54 0.34 
1:300 2.39 0.94 0.43 0.32 
1:400 2.49 0.87 0.35 0.16 
 
 
 
Figure 16. Combination effect of QW-296 and MDB5 with various ratios against 
PC3-TXR cells for 72h.  
 
 
 
 
 
 
 
 
Note: Q: QW-296; M: MDB5; Fa: fraction affected (%); CI > 1.1: antagonism; 0.9 
< CI < 1.1: additivity; CI < 0.9: synergism  
51 
 
3.3.3 Inhibition of colony formation 
The inhibitory activity of QW-296, MDB5 and their combination on 
tumorigenic potential in PC3-TXR cells was determined by colony formation assay. 
As shown in Figure 17, it was not surprised that the number of colonies in 
untreated group was the maximum compared with that of QW-296 alone, MDB5 
alone, or the combination treated group. MDB5 at concentration of 15 μM exhibited 
slight inhibition against colony formation, while QW-296 at concentration of 100 
nM markedly suppressed the colony formation. However, combination of QW-296 
at 50 nM and MDB5 at 15 μM almost resulted in no colony formation throughout 7 
days. These data further confirmed the synergistic effect of QW-296 and MDB5 for 
treating advanced prostate cancer.  
 
 
 
 
Figure 17. Effect of QW-296 and MDB5 on colony formation of PC3-TXR cells. 
300 PC3-TXR cells per well were seeded to 6-well culture plates. At 24h, drug 
formulations were added and at 7 days, cell colonies were fixed, stained and counted. 
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3.3.4 Effect of combination therapy on cell cycle, apoptosis and protein 
expression 
Cell cycle analysis and apoptosis was determined by PI-staining after 48 h 
or 72 h of treatments to PC3-TXR cells (Figure 18). The data showed that QW-
296 (100 nM) caused immediate 35.84% G2/M phase arrested at 48 h, but the 
percentage of arrested cells in G2 phase decreased to 25.76% with increase of 
treatment time at 72 h. Meanwhile, QW-296 treatment could induce sub-G1 phase 
arrest to 9.79% at 48 h and 11.43% at 72 h. In contrast to QW-296, MDB5 (15 µM) 
resulted in 57.99% of cells arrested in G0/G1 phase at 48 h, along with 72.85% of 
arrested cells in G0/G1 at 72 h, suggesting MDB5 affected on cell cycle through 
different mechanism and it worked at a slow manner. The combination of QW-296 
at 50 nM and MDB5 at 15 µM induced overall G2/M arrest at 48 h and 72 h. Unlike 
single treatment changing cell arrest dramatically from 48 h to 72 h, combination 
therapy caused cell arrested in G2 phase and these cells ended up in static status 
throughout 72 h. Noticeably, after combination treatment the cell percentage of 
PC3-TXR in sub-G1 phase was significantly enhanced to 19% compared with cell 
percentage after monotherapy.  
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Meanwhile, as mentioned at the beginning of this paper, MDB5 was 
designed as Hh signaling inhibitor and GDC-0449 analog, thus we determined the 
effect of monotherapy or combination therapy on Hh signaling-related protein 
expression. We found clear reduction of Shh proteins in MDB5 treated group and 
combination treated group (Figure 19).  
 
 
Figure 18. Effect of QW-296 and MDB5 on cell cycle and apoptosis of PC3-TXR 
cells. Cells were treated for 48 h or 72 h, stained with propidium iodide (PI), and 
analyzed on a flow cytometer. (A) 48 h, (B) 72 h. Results were expressed as the mean 
± SEM (n=3). 
 
 
 
 
A
B
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3.3.5 Characterization of copolymer mPEG-p(TMC-MBC)  
Monomer 2-Methyl-2-benzyloxycarbonyl-propylene carbonate (MBC) was 
synthesized first as described previously. Then MBC and trimehtylene carbonate 
(TMC) were copolymerized with methoxy PEG5000 using Sn(Oct)2 as a catalyst to 
yield 1.82 g of copolymer mPEG-p(TMC-MBC) (88% yield). In 1H NMR spectrum 
of mPEG-p(TMC-MBC), the following peaks were observed at δ 2.03 (CH2, br, 2H) 
corresponding to TMC, δ 1.2 (CH3, s, 3H) and δ 7.3 (phenyl, m, 5H) corresponding 
to MBC, δ 4.2-4.3 (CH2, t, 4H) corresponding to both TMC and MBC, and δ 3.63 
(CH2, s, 2H) corresponding to PEG. The Mn of mPEG-p(TMC15-MBC15) determined 
by 1H NMR was 10280 g/mol with 15 units of each block, respectively. (Figure 20). 
 
 
 
Figure 19. Effect of QW-296 and MDB5 on Hedgehog signaling protein 
expression of PC3-TXR cells. 
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Figure 20. Synthetic route of copolymer mPEG-p(TMC-BC) (A) and its 1H NMR 
spectra (B). 
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3.3.6 Characterization, quantification and release profile of drug-loaded 
mPEG-p(TMC-MBC) micelles 
The amphiphilic nature of mPEG-p(TMC-MBC) drives self-assembly into 
micelles in aqueous buffer. Surface morphology and mean particle size of micelles 
were checked by transmission electron microscopy (TEM, Tecnai G2 Spirit) and 
dynamic light scattering (DLS, Zetasizer Nano ZS90). Unloaded, QW-296-loaded 
and MDB5-loaded polymeric micelles had similar size distributions, which were 81 
nm. The TEM image also showed that the micelles had a narrow size distribution 
below 60 nm (Figure 21C) and confirmed that mPEG-p(TMC-MBC) formed 
spherical micelles in PBS with distinct boundaries as anticipated. CMC value of 
mPEG-p(TMC-MBC) was 6.65×10-4 g/L (Figure 21D), further indicating that the 
micelles were quite stable in PBS. Meanwhile, high drug payload of these 
polymeric micelles was determined by HPLC: 8.13±0.75% (w/w) for QW-296 and 
9.12±0.69% (w/w) for MDB5, respectively (Table 2).  
Table 2. Parameters of mPEG-p(TMC-BC) micelles 
Mean 
size (nm) 
zeta 
potential 
(mV) 
PDI CMC (g/L) 
Drug loading 
of QW-296 
Drug loading 
of MDB5 
81.51 -1.45 0.143 6.65×10-4 8.13±0.75% 9.12±0.69% 
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To improve the bioavailability of QW-296 and MDB5 for cancer treatment, 
controlled and sustained drug release is very important. Therefore, the release 
profile of QW-296 and MDB5 from mPEG-p(TMC-MBC) micelles at different pH 
was carried out by a dialysis method in PBS buffer (pH 7.4) and acetate buffer (pH 
6.5). As shown in Figure 22, 40% of QW-296 or 25% of MDB5 was rapidly 
released from the micelles within the initial 12 h. Then the release of QW-296 or 
MDB5 increased up to 75% or 65% at 48 h followed by slower sustained profile 
until the end of the 96 h. Furthermore, at pH 6.5, the liberation of QW-296 or MDB5 
from polymeric micelles was accelerated as expected due to the instability of 
micelles occurred in an acidic or basic environment.  These data suggested that 
 
 
 
Figure 21.  Characterization of polymeric micelles. (A) Hydrodynamic diameter, (B) 
zeta potential, (C) TEM morphology, (D) critical micelle concentration. 
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the drug-loaded micelles could release these drugs at expected speed under 
physiologically simulating conditions. 
 
3.3.7 In vivo antitumor efficacy in Orthotopic Prostate Cancer Mouse Model  
We successfully established orthotopic prostate tumor in 8-week-old male 
athymic nude mice by injecting 1.5x106 PC3TXR-luc cells into dorsal prostate lobe 
(Figure 23). The mice whose bioluminescent radiance reached 108 were 
randomized into five groups: 1) control, 2) QW-296 micelles (10 mg/kg), 3) MDB5 
micelles (10 mg/kg), 4) combination of QW-296 and MDB5 in cosolvent (5 mg/kg 
+ 5 mg/kg), 5) combination of QW-296 and MDB5 in micelles (5 mg/kg + 5 mg/kg).  
 
 
 
Figure 22. In vitro release of QW-296 and MDB5 from drug encapsulated 
micelles at pH 7.4 and 6.5. (A) QW-296, (B) MDB5. Drug concentrations from each 
time point were measured by HPLC and drug release profiles were represented as 
the mean± SEM. 
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All the treated groups showed inhibition of tumor growth compared with 
control group, however, the maximum tumor inhibition was observed in the group 
treated with combination in micelles. Notably, combination of QW-296 and MDB5 
in micelles exhibited stronger antitumor activity in comparison with combination 
with same doses in cosolvent (Figure 24).  
 
 
 
 
Figure 23. In vivo imaging of athymic nude mice bearing PC3-TXR orthotopic 
prostate cancer. Representative bioluminescence images were took at day 7 and 
day 24 (n = 6). 
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Next, we performed immunohistochemical analysis to further elucidate the 
superior anticancer efficacy of combination micelles. Hematoxylin and eosin (H&E) 
stain of tumor sections indicated that tumor samples from four treated groups had 
more necrotic area compared with tumor samples from control group, and tumors 
from combination micelles group showed maximum necrosis. Furthermore, 
 
 
 
Figure 24. In vivo efficacy of QW-296 and MDB5 after systemic administration in 
PC3-TXR orthotopic prostate cancer bearing athymic nude mice. Representative 
tumors of each group were excised after sacrificing the mice at the end of the 
experiment. 
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cleaved caspase 3 stain indicated the induction of significant apoptosis by 
combination micelles of QW-296 and MDB5 compared to other treatments (Figure 
25). Meanwhile, the chronic toxicities of these treatments were also examined by 
histological analysis of major organs. No distinct histological changes were 
observed in the liver, spleen, kidney and heart from all treated groups, suggesting 
that mice tolerated all treatments well (Figure 26). 
 
 
 
 
Figure 25. Analysis of tumor samples by hematoxylin and eosin (H&E) and 
Caspase 3 stain. Tumor samples from control and treated groups were excised, fixed 
and immunostained for (A) H&E and (B) Caspase 3. 
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3.4 DISCUSSION 
Drug resistance is still one of the major impediments for the success of 
chemotherapy and several factors account for the occurrence of resistance, 
including ATP-binding cassette transporter family (P-gp, ABCC1, ABCG2, etc.) 
 
 
 
Figure 26. Analysis of major organs by H&E stain. Organ samples from five groups 
were excised, fixed and stained for H&E. No obvious histological changes were 
observed in the livers, spleens, kidneys and hearts from all the treated groups. 
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[88], alteration in drug targets, as well as intrinsic chemoresistance (cancer stem 
cells, CSCs) [89]. With the advances in cancer research, there are numerous 
approaches to overcome drug resistance. Combination chemotherapy is 
considered as one of the preferred choice in both preclinical research and clinical 
practice. Due to heterogeneity and molecular complexity of cancers, combination 
therapy referring to administration of two or more anticancer agents with different 
mechanisms of action can modulate various signaling pathways and maximize 
therapeutic effects. In addition, it is worth mentioning that if the combinatory drug 
effect is greater than the sum of their individual effects, as known as drug 
synergism, there will be a higher chance in success of combination strategy. In this 
regard, our study proposed a synergistic combination chemotherapy using two 
novel anticancer agents to overcome taxane-resistance and treat advanced 
prostate cancer.  
To replace taxane treatment, we first designed and synthesized a new 
microtubule destabilizer, QW-296, whose function on microtubule mass, different 
from the stabilizers such as taxanes, was to suppress tubulin polymerization. On 
the other hand, a novel Hh pathway inhibitor MDB5 was selected to ally with QW-
296 to treat advanced prostate cancer due to the emerging clinical reports that 
over-expressed Hh pathway promotes prostate tumor formation from epithelial 
cells, renders the epithelial-to-mesenchymal transition, and has cross-talk with 
androgen pathway. In our previous study, we also demonstrated that the 
combination of Hh inhibitor cyclopamine and paclitaxel effectively worked together 
to suppress the growth of taxane-resistant prostate cancer in vitro and vivo by 
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playing different roles on cancer cells, suggesting a promising combination 
strategy. Thus, in the current study, we upgraded Cyclopamine to a newly 
designed Hh signaling inhibitor MDB5, having stronger inhibition activity against 
Hh signaling but less unfavorable toxicity compared with its parent drug GDC-0449.  
First, the inhibitory effect of QW-296 and MDB5 on prostate cancer cells was 
confirmed by cell viability and colony formation assay, clearly indicating the benefit 
of this combination, and then their synergism was proved by Chou–Talalay method, 
which strengthened our hypothesis preliminarily. In the following cell cycle analysis, 
QW-296 and MDB5 made distinct impacts on cell cycle as QW-296 treatment 
caused G0/G1 phase arrest while MDB5 treatment lead to G2/M phase arrest, 
which demonstrated two anticancer agents worked at complementary mechanism 
of action against PC3-TXR cells, and this result was in the agreement with previous 
reports. In further we analyzed the expression change of relevant protein to 
highlight the combination advantage at molecular level. We observed Shh, a key 
downstream component of Hh signaling pathway, were highly downregulated after 
MDB5 monotherapy or combination of QW-296 and MDB5, indicating the 
treatment did have effect on Hh pathway. All these results reinforced our 
preliminary findings and provided us with a reasonable explanation on benefits of 
the combination therapy.    
Although QW-296 and MDB5 demonstrated excellent synergy of anticancer 
activity against chemoresistant prostate cancer, their clinical translation will be 
limited due to their intrinsic poor aqueous solubility as many other anticancer 
agents. Therefore, to solve this problem, nanoparticle-based therapeutic systems 
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have emerged as a promising platform for delivering hydrophobic drugs over 
several decades. In this study, we developed an amphiphilic copolymer mPEG-
p(TMC-MBC) to encapsulate two hydrophobic small molecules, thereby forming 
polymeric micelles in aqueous solution with nano-ranged particle size that are 
suitable for systemic therapy in animal study. PEG5000 was used as hydrophilic 
backbone and this long length enabled us to synthesize the copolymer with 
molecular weight in the range of 10,000-11,000 Da. Its stealth-like property helped 
resulting micelles prolong circulation time and accumulate the amount of drug at 
target tumor tissue. On the other hand, two carbonate blocks TMC and MBC 
provided desired hydrophobicity to wrap lipophilic molecules in the core and 
balance hydrophilic composition as well. Our results also confirmed that polymeric 
micelles mPEG-p(TMC-MBC) enabled appropriate drug loading for both drugs and 
sustained drug release in acidic or neutral condition, which laid a foundation for 
the success of combination therapy applied in animals or future clinical translation. 
To better investigate the combination efficacy, we used half dose of QW-
296 and MDB5 in combination treatment as compared with monotherapy. All the 
four treated groups exhibited excellent tumor inhibitory results. However, 
combination therapy in micelles showed significantly enhanced reduction in tumor 
size compared with the combination in co-solvent as well as QW-296 or MDB5 
monotherapy. Apart from tumor growth suppression, H&E stain of vital organs 
demonstrated the micelles carrying QW-296 and MDB5 were well tolerated, as 
other healthy organs did not show obvious histological changes after treatments. 
These results strongly supported our hypothesis that QW-296 and MDB5 could 
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synergistically treat chemoresistant prostate cancer in vivo and copolymer mPEG-
p(TMC-MBC) could serve as a more effective delivery vehicle to boost anticancer 
activity of two drugs than co-solvent.  
3.5 CONCLUSION 
In the present study, we successfully synthesized and screened a novel 
microtubule destabilizer QW-296 and a Hh pathway inhibitor MDB5 and 
demonstrated their anticancer activities in combination or individually. The 
copolymer mPEG-p(TMC-MBC) was successfully synthesized and formed 
polymeric micelles to encapsulate QW-296 and MDB5 with desirable drug payload 
and small particle sizes. The overall findings indicated that the combination of QW-
296 and MDB5 exhibited the synergistic therapeutic effect against chemoresistant 
prostate cancer via different mechanism, and with the help of mPEG-p(TMC-MBC) 
the combination could effectively inhibit the growth of chemoresistant prostate 
cancer in vivo. Given these encouraging results, our micelles of QW-296 and 
MDB5 provide a promising therapeutic strategy for chemoresistant prostate cancer 
therapy. 
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CHAPTER 4 POLYMER CONJUGATE OF A MICROTUBULE 
DESTABILIZER INHIBITS LUNG METASTATIC MELANOMA2 
4.1 INTRODUCTION 
Over the past several decades, the development of nanomedicines has 
been driven by the increasing demands of delivering therapeutic agents to disease 
sites efficiently. A large amount of pioneering research has highlighted applications 
of micelles, nanoparticles, liposomes, polymersomes, nanogels and dendrimers 
as nanocarriers of low molecular-weight drugs, oligonucleotides and genes. 
Polymer-drug conjugates debuted in 1955 [90], and in the mid-1970s Ringsdorf 
proposed the idea of conjugating therapeutic agents to water soluble polymers [91]. 
Since then, the field of polymer-drug conjugates started a new era of drug delivery 
and has been growing fast. Advantages of conjugates over their corresponding 
parent drugs include: 1) increased aqueous solubility of hydrophobic drugs; 2) 
prolonged blood circulation time; 3) enhanced bioavailability; 4) increased 
protection of drugs from degradation; 5) increased tumor accumulation either due 
to enhanced permeability and retention (EPR) effect or tunable targeting moieties. 
Unlike physically drug encapsulation into nanoparticles and micelles, covalent 
drug conjugation to polymers achieves enhanced drug payload and prevents 
premature drug release, thereby decreasing undesired toxicities compared to 
physically drug-encapsulated liposomes, nanoparticles and micelles. The polymer-
                                                          
2 R. Yang, G. Mondal, R.A. Ness, K. Arnst, V. Mundra, D.D. Miller, W. Li, R.I. Mahato, Polymer 
conjugate of a microtubule destabilizer inhibits lung metastatic melanoma, J. Control. Release. 
249 (2017) 32-41. 
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drug conjugate market is currently becoming well-established with several 
commercialized products available for a wide range of disease states, such as 
Adynovate by Baxalta, Movantik™ by AstraZeneca, Oncospar® by Enzon 
Pharmaceuticals, Plegridy® by Biogen, etc.  
Malignant melanoma is the most invasive form of skin cancer with high 
metastatic propensity, typically metastasizing to the lymph nodes, lungs, liver, 
brain and heart at late stage of melanoma. The median overall survival time of 
patients suffering from metastatic melanoma is less than one year, and only about 
10% of these patients survive more than 5 years after diagnosis [92]. Unfortunately, 
the survival of patients with advanced metastatic melanoma has not been 
significantly improved by current Food and Drug Administration (FDA)-approved 
systemic chemotherapies [93]. Dacarbazine (DTIC), a widely used 
chemotherapeutic agent for treatment of metastatic melanoma, shows transient 
efficacy in most patients, however, only 1–2% of patients achieve a durable long-
term response to this therapy [94]. The combination of paclitaxel and carboplatin 
is used as second-line therapy for patients who suffer from disease progression 
while receiving DTIC treatment. Clinical benefit of this combination therapy was 
noted in more than 40% of all patients in the original study [95,96]. Nevertheless, 
a potential problem when using paclitaxel or other microtubule inhibitors for cancer 
treatment in the long term is that their anticancer effects could be undermined by 
intrinsic or acquired drug resistance due to overexpression of drug efflux pumps 
(P-glycoprotein, MRP and BCRP) in cancer cells [71-73]. To address this problem, 
we have synthesized a series of novel microtubule destabilizers, substituted 
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methoxybenzoyl-ary-thiazole (SMART) compounds, with nanomolar anticancer 
activity against melanoma, breast cancer, ovarian cancer, colon cancer and 
prostate cancer [97].  In addition, their ability to circumvent P-gp mediated drug 
resistance was confirmed by using prostate cancer cells with P-gp overexpression 
[98]. However, the clinical translation of SMART compounds is limited due to their 
poor aqueous solubility as many other anticancer agents. Moreover, these small 
molecular weight drugs are rapidly eliminated from the circulation, requiring 
frequent dosing, leading to increased risk of side effects. To address this issue, we 
formulated SMART-100 in micelles using poly (ethylene)-b-poly(D,L-lactide) 
(PEG-PLA) in a previous study, but the utility of physical encapsulation is limited 
by low drug payload. Therefore, in the current study we synthesized a new SMART 
analogue, SMART-OH and conjugated this compound to the carboxyl pendant 
groups of poly (ethylene glycol)-block-poly (2-methyl-2-carboxyl-propylene 
carbonate) (mPEG-b-PCC). The polymeric conjugate consists of three 
components including biocompatible PEG blocks, a biodegradable polycarbonate 
backbone and lipid chains of dodecanol (DC). The anticancer effect of SMART-
OH and its polymer-drug conjugate mPEG-b-PCC-g-SMART-g-DC (abbreviated 
as P-SMART) on melanoma cells was determined. Furthermore, a mouse model 
of metastatic melanoma to the lungs was established to study in vivo efficacy of P-
SMART as well as SMART-OH.  
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4.2 METHODS 
4.2.1 Materials 
4-Cyanophenol, L-cysteine, N,N,N′,N′-tetramethyl-O-(1H-benzotriazol-1-
yl)uranium hexafluorophosphate (HBTU), tert-butyldimethylsilyl chloride 
(TBDMSCl), n-butyllithium, tetra-n-butylammonium fluoride, 2, 2-
bis(hydroxymethyl) propionic acid, methoxy poly(ethylene glycol) (mPEG, Mn 
=5000), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), N-(3-dimethylaminopropyl)-
N′-ethylcarbodiimide hydrochloride (EDC) 98%, 1-hydroxybenzotriazole (HOBT), 
Benzyl bromide, Dodecanol (DC), diisopropylethylamine (DIPEA) and cremophor® 
EL were purchased from Sigma Aldrich (St. Louis, MO).  FxCycle™ PI/RNase 
staining solution was purchased from ThermoFisher Scientific (Waltham, MA). 
Bovine brain tubulin was purchased from Cytoskeleton (Denver, CO). 
4.2.2 Synthesis and characterization of SMART-OH 
 2-(4-Hydroxyphenyl)-4,5-dihydrothiazol-4-yl-3,4,5-
trimethoxyphenyl)methanone (abbreviated as SMART-OH) was synthesized as 
shown in Figure 27 (compound 5). Briefly, 4-cyanophenol (1 equiv.) was mixed 
with L-cysteine (1 equiv) in a 1:1 solution of MeOH/pH 6.4 PBS. The reaction 
mixture was heated to 40 °C and stirred for 3 days. The mixture was then filtered 
to remove the precipitate and MeOH was removed using a rotary evaporator. The 
remaining solution was then acidified to pH 4 using 1M HCl and CH2Cl2 was added 
to the solution. The resulting precipitate was filtered to yield a white solid, 
compound 1. This solid was dried overnight in a vacuum desiccator and then used 
directly for the next step.  
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Compound 1 (1 equiv.) was dissolved in anhydrous CH2Cl2. HBTU (1.1 
equiv) was then added and stirred for 15 minutes. This was followed by addition of 
DIPEA (2.2 equiv) which was stirred for 2-3 minutes. Finally, HNCH3OCH3 HCl salt 
(1.1 equiv.) was added and the reaction was stirred at room temperature for 12-18 
hours. The reaction mixture was washed once with ddH2O and twice with saturated 
NaCl solution. The organic layer was then dried over MgSO4. The solvent was 
removed by a rotary evaporator to yield crude yellow oil. This was then purified by 
flash chromatography to obtain compound 2. 
A solution of compound 2 (1 equiv.) in anhydrous tetrahydrofuran (THF) 
was kept under argon and cooled to 0 °C. Imidazole (2.5 equiv.) and TBDMSCl (2 
equiv) were then added to the solution and the mixture was stirred for 12-18 hours. 
The solvent was removed by a rotary evaporator and the resulting solid was 
dissolved in CH2Cl2 and washed once with ddH2O and once with saturated NH4Cl 
solution. The organic layer was dried over NaSO4 followed by purification using 
flash chromatography to yield compound 3.  
Compound 3 (1 equiv) was dissolved in freshly distilled THF at room 
temperature while 3,4,5-methoxylphenyl (1.2 equiv) was dissolved in freshly 
distilled THF in a separate flasks and cooled to -78 °C under argon.  n-Butyllithium 
(1.5 equiv) was then added to the cooled mixture and stirred at -78 °C for 30 
minutes. The solution containing compound 3 was then added to the mixture and 
stirred for 2 hours while returning to room temperature. The reaction was quenched 
with saturated NH4Cl solution, extracted three times with ethyl acetate, dried over 
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NaSO4, and purified by flash chromatography to yield a bright yellow solid, 
compound 4. 
Compound 4 (1 equiv) was then dissolved in THF and cooled to 0 °C. Tetra-
n-butyl ammonium fluoride (2 equiv) was then added and the mixture was stirred 
for 10 minutes. The reaction was quenched with saturated NH4Cl solution, 
extracted three times with ethyl acetate, dried over NaSO4, and purified using flash 
chromatography to yield the final pure product (compound 5, Figure 27).  
4.2.3 Docking 
Docking studies were carried out using the crystal structures of the α,β-
tubulin dimer in complex with DAMA-colchicine (Protein Data Bank code 1SA0). 
Schrodinger Molecular Modeling Suite 2016 (Schrodinger Inc., Portland, OR) 
running on Microsoft Windows 7 platform was used to perform these studies, 
similar to what we described in previous reports [99-101]. Briefly, the protein-ligand 
complex was prepared using the Protein Preparation module, and SMART-OH 
was docked into the colchicine binding site in the structure of 1SA0 using Glide 
module. Data analyses were performed using the Maestro interface of the software.   
4.2.4 Tubulin polymerization assay 
Bovine brain tubulin (3.33 mg/m) was exposed to 10 µM of SMART-OH, 
colchicine or vehicle control (5% DMSO), respectively, and incubated in 100 µl of 
general tubulin buffer (80 mM PIPES, 2.0 mM MgCl2, 0.5 mM EGTA and 1 mM 
GTP; pH 6.9). Absorbance at 340 nm was monitored at 37°C every minute for 15 
min by the SYNERGY 4 Microplate Reader (Bio-Tek Instruments, Winooski, VT).  
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4.2.5 Synthesis and characterization of mPEG-b-PCC-g-SMART-g-DC (P-
SMART) 
2-Methyl-2-benzyloxycarbonyl-propylene carbonate (MBC), poly(ethylene 
glycol)-block-poly(2-methyl-2-benzoxycarbonyl-propylene carbonate) (mPEG114-
b-PBC28) and poly(ethylene glycol)-block-poly(2-methyl-2-carboxyl-propylene 
carbonate) (mPEG114-b-PCC28) were synthesized as described previously [54]. 
SMART-OH and DC were conjugated to the carboxyl groups of mPEG114-b-PCC28 
copolymer using carbodiimide coupling. MPEG-b-PCC (180 mg, 0.019 mmol) was 
dissolved in anhydrous CH2Cl2 followed by addition of EDC (215 mg, 1.12 mmol), 
HOBT (101 mg, 0.75 mmol) and the solution was stirred at room temperature. After 
two hours, N,N-diisopropylethylamine (DIPEA, 98 μl, 0.56 mmol) and SMART-OH 
(84 mg, 0.23 mmol) were added and the reaction continued for two days. Then, 
DC (70 mg, 0.37 mmol) was added and the reaction was allowed to proceed for 
one additional day (Figure 29A). Crude product was purified by precipitation in 
large excess of diethyl ether and then by dialysis against MeOH using a 
regenerated cellulose membrane with 3.5 K MWCO.  
1H NMR spectrum was recorded on a Bruker (500 MHz, T = 25 °C) using 
DMSO-d6 as solvent for P-SMART in a chemical shift range of 0-12 ppm. 
 Dynamic light scattering (DLS) was used for measuring the particle size 
distribution of P-SMART. Briefly, 10 mg of P-SMART was dissolved in CH2Cl2 and 
the solvent was evaporated under reduced pressure. The resulting film was 
hydrated with 1 ml PBS (pH 7.4) followed by sonication and filtration through 0.22 
μm filter. Mean particle size was measured by using a Zetasizer Nano ZS90 
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(Malvern, Worcestershire, UK) at a scattering angle of 173°. A total of 12 
measurements were taken per sample with a time span of 10 s. Particle size 
distribution was reported as the mean ± SEM. of three independent samples.  
4.2.6 Quantification of SMART payload in P-SMART 
To quantify the conjugated drug, alkaline hydrolysis method was used. 1 
mg/ml P-SMART was mixed with 1 ml NaOH (1 N) at 37 °C overnight. Samples 
were then neutralized to pH 7.4 followed by HPLC-PDA analysis. Chromatography 
was performed on Phenomenex® column (250×4.6 mm; 5 μm) using acetonitrile 
and water (60:40, v/v) as mobile phase and wavelength of 300 nm. The stability of 
SMART-OH was also tested under the same alkaline hydrolysis conditions at 37 °C 
overnight to determine if there was any degradation of SMART-OH. The data was 
reported as the mean ± SEM of three individual experiments. Payload was 
calculated using equation 1. 
Payload (
𝑤
𝑤
%) =
amount of hydrolysed drug
total weight of polymer drug conjugate
× 100% 
4.2.7 In vitro drug release 
Drug release from the P-SMART conjugate was determined at pH 6.5 and 
7.4. Briefly, 1 mg of P-SMART was suspended in 1 ml buffer solution (0.1 M acetic 
acetate, pH 6.5 or 0.1 M PBS, pH 7.4) and diluted with MeOH in a volume ratio of 
MeOH: aqueous solution (1:4, v/v). All samples were incubated at 37 °C, shaken 
at 100 rpm for 0, 3, 6, 9, 12, 24, 48, 72, 96, 120 h, and neutralized to pH 7.4 prior 
to HPLC analysis as described in previous section. All experiments were 
performed in triplicate and the data reported as the mean ± SEM of three individual 
experiments. 
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4.2.8 Cell culture  
Human melanoma cell line A375, mouse melanoma cell lines B16-F10 and 
B16-F10-luc were cultured in DMEM medium supplemented with 10% FBS and 1% 
penicillin/streptomycin. All cell lines were grown and maintained in a humidified 
incubator containing 5% CO2 at 37 °C. 
4.2.9 Cytotoxicity assay  
A375 and B16-F10 cells were used to determine the cytotoxicity of P-
SMART and parent drug. After attached to the bottom of plate, cells were 
incubated with different concentrations of SMART-OH or P-SMART for another 72 
h. Cell viability was determined by MTT assay and the absorbance was measured 
at 560 nm with subtraction of absorbance at 630 nm. Each group was performed 
in triplicate and the data reported as the mean ± SEM.
 
4.2.10 Colony formation assay   
A375 or B16-F10 cells were seeded at 250 cells/well into 6-well plates and 
allowed to attach for 24 h. Cells were then treated with SMART-OH or P-SMART 
at different concentrations. After a 7 day-incubation, colonies in each well were 
fixed by 10% formalin, stained with 0.5% crystal violet solution and visualized 
under a microscope. Each group was performed in triplicate. 
4.2.11 Transwell invasion assay 
Cell invasion experiments were carried out using 24-well plates and cell 
culture inserts with 8 μm pore size (Corning®). The upper sides of the inserts were 
coated with 40 μL Matrigel® diluted 1:4 (v/v) with serum-free DMEM, were placed 
in a 24-well plate, and were incubated for 2 h at 37 °C. B16-F10 cells were 
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suspended in serum-free DMEM and placed in the upper chamber of the Transwell 
insert (1×105 cells/ml) with treatment of SMART-OH or P-SMART at a dose of 0.5 
μM. Cell suspension without treatment was used as a control. DMEM containing 
10% FBS was added to the corresponding lower chamber. After 24 h, the non-
invaded cells in the upper chamber were removed by a cotton swab and the 
invaded cells were fixed with 10% formaldehyde in PBS and stained with 0.5% 
crystal violet solution. Each group was conducted in triplicate wells and three 40X 
imaging areas were randomly selected for each well. 
4.2.12 Cell cycle analysis by propidium iodide staining 
A375 and B16-F10 cells were used for cell cycle analysis. Cells were 
cultured in a 24-well plate to 80% confluence and treated with P-SMART for 48 h. 
Cells were harvested, fixed in 70% ice-cold ethanol for 1 h and washed by PBS. A 
cell pellet containing 1x106 cells was then re-suspended in 0.5 mL of FxCycle™ 
PI/RNase staining solution and incubated for 15 min at room temperature. Cell 
cycle was measured by a flow cytometer (BD FACSCalibur NJ). Results from 
20,000 fluorescent events were obtained for analysis. 
4.2.13 In vivo study 
All animal experiments were performed in accordance with the NIH animal 
use guidelines and protocol approved by the Institutional Animal Care and Use 
Committee (IACUC) at the University of Nebraska Medical Center (UNMC), 
Omaha, NE. A mouse model of metastatic melanoma to the lung was established 
in 8 week-old female C57BL/6 albino mice by injecting 2 × 10
5 B16-F10-luc cells 
suspended in 100 μL PBS into their tail vein. Mice were randomly divided into three 
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groups of five animals per group when the radiance of tumor had reached 105. 
SMART-OH and P-SMART were administered intravenously to mice once every 
three days for a total of five times. Group 1 was kept as the control and received 
normal saline, group 2 received 20 mg/kg SMART-OH in 35 % of cosolvent (50% 
propylene glycol, 30% Cremophor® EL, and 20% ethanol) and 65 % of dextrose 
solution, and group 3 received 20 mg/kg P-SMART (equivalent to free SMART-
OH). Bioluminescent radiance of tumor was measured every other day using IVIS® 
Spectrum imaging system (PerkinElmer Inc., MA). At the end of the animal study 
(i.e., day 24), mice were sacrificed and tumors as well as vital organs (liver, spleen, 
kidney and heart) were excised.  
In a separate survival study, mice were randomly divided into three groups 
of seven mice for different treatments as described above.  Survival observation 
of mice ceased when death occurred due to uncontrolled tumor growth or the 
toxicity of treatments. Three representative tumor tissues were collected per group 
and fixed with 10% buffered formalin for 24h. The fixed samples were embedded 
in paraffin and thin sections of 4 μm were obtained and immunostained for 
hematoxylin and eosin (H&E) and cleaved Caspase 3.  
4.2.14 Statistical analysis 
Data were represented as the mean ± SEM. The statistical comparisons of 
the experiments were performed by two-tailed Student’s t test. P <0.05 was 
considered statistically significant.  
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4.3 RESULTS 
4.3.1 Characterization and molecular docking of SMART-OH in tubulin 
The structures for all synthesized compounds were characterized and 
confirmed by NMR and high resolution mass spectrometry. The proton NMR for 
final compound 5 (SMART-OH) was shown in Figure 27.  
 
Docking studies (Figure 28A) indicated excellent binding and interactions 
between SMART-OH and the tubulin dimer. SMART-OH and the native ligand in 
the crystal structure of 1SA0 showed good overlap when they bind to the colchicine 
 
Figure 27. Synthesis and characterization of SMART-OH. 
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binding site in tubulin (Figure 28A, enlarged portion). Three hydrogen bonds were 
formed between SMART-OH and the tubulin dimer, namely oxygen in the 4-
methoxy moiety to Cys241; the carbonyl to Asp-251; and the phenol to Val315. 
These three hydrogen bonds anchor SMART-OH tightly in this colchicine binding 
pocket, predicting effective disruption of tubulin polymerization. 
 
4.3.2 Inhibition of tubulin polymerization  
To evaluate the ability of SMART-OH to directly interact with tubulin and 
confirm its mode of action, we performed a microtubule polymerization assay in 
vitro. A vehicle and colchicine (10μM), a well-known microtubule destabilizing 
agent, were used as controls and assayed under the same conditions. Robust 
polymerization is observed in the control group, while both SMART-OH and 
colchicine effectively inhibit polymerization (Figure 28B). This result is consistent 
 
 
Figure 28. Inhibition of SMART-OH on tubulin. A) Molecular docking. Docking 
image showed that SMART-OH bind to the colchicine binding site in tubulin. B) Tubulin 
polymerization assay. Tubulin (3.33 mg/ml) was exposed to 10 µM of SMART-OH, 
colchicine or vehicle control (5% DMSO), respectively, and incubated in general 
tubulin buffer. Absorbance at 340 nm was monitored at 37°C every minute for 15 min. 
Both SMART-OH and colchicine effectively inhibited polymerization, while robust 
polymerization was observed in the control group. 
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with the proposed mechanism of action of SMART-OH compound as a potent 
tubulin polymerization inhibitor. 
4.3.3 Characterization and quantification of P-SMART 
P-SMART was synthesized by direct carbodiimide coupling of SMART-OH 
onto the pendant carboxylic acid groups of the hydrophobic block of mPEG-b-PCC 
copolymer (Figure 29A). In 1H NMR spectrum of mPEG-b-PCC, protons 
corresponding to −CH2−CH2−O− of PEG at δ3.4−3.6, −CH2− units of PCC at 
δ4.2−4.4 and −COOH at δ12−14 were observed and reported earlier by our group. 
After conjugation of SMART-OH to mPEG-b-PCC, protons corresponding to 
SMART were all observed in 1H NMR spectrum.1H NMR (500 MHz, DMSO-d6) 
spectrum of mPEG-b-PCC-g-SMART-g-DC showed peaks corresponding to PEG: 
(−CH2−CH2−O-) at δ3.5, PCC: (−CO-O-CH2-C-) at δ4.2 (m, 4H), (−CO-O-CH2-C-
CH3) at δ1.1-1.3 (t, 3H), Dodecanol: CH3-(CH2)9- at δ0.9 (t, 3H), CH3-(CH2)9- at 
δ1.0-1.3 (bs, 18H), CH3-(CH2)9-CH2 at δ1.6 (m, 2H), CH3-(CH2)9-CH2-CH2- at δ4.3 
(m, 2H), SMART-OH: benzene -CH- at δ8.1 (dt, 2H), δ7.6 (dt, 2H), δ7.2 (t, 2H), 
thiazole -CH- at δ8.7 (s, 1H), -OCH3 at δ3.83 (s, 6 H) and δ3.71 (s,3 H) (Figure 
29B). 
DLS showed the mean particle size of P-SMART was 71.51±0.47 nm (PDI: 
0.055 ± 0.011) (Figure 29C). Naked SMART-OH was stable under alkaline 
hydrolysis condition and drug payload of conjugated SMART-OH was determined 
by HPLC analysis as 14.3±2.8 % (w/w). 
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4.3.4 PH dependent drug release 
In vitro drug release studies were carried out in PBS at pH 7.4 and acetate 
buffer at pH 6.5 to simulate drug release in blood and tumor environment. P-
SMART showed a slow but sustained release of SMART-OH. There was no 
noticeable initial burst release at the different pH and no significant drug release 
at neutral conditions afterwards. At pH 6.5, the liberation of SMART-OH from P-
SMART was accelerated as expected due to the increased cleavage of ester 
linkages known to occur in an acidic or basic environment. After five days, more 
than 25% of SMART-OH was released at pH 6.5, but only 15% of SMART-OH at 
pH 7.4 (Figure 29D). 
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4.3.5 Anticancer activity  
We determined the anticancer activity of P-SMART as well as parent drug 
SMART-OH on A375 and B16-F10 cells for 72 h. Due to the slow release of 
SMART-OH from the polymer conjugates, the IC50 of P-SMART increased to 0.75 
μM in two cell lines while IC50 of SMART-OH was 75 nM in A375 cells and 150 nM 
in B16-F10 cells. P-SMART effectively killed 80% of melanoma cells at 2 μM parent 
drug equivalent dose (Figure 30A). 
 
 
Figure 29. Synthesis and characterization of mPEG-b-PCC-g-SMART-g-DC (P-
SMART). A) Synthetic scheme of P-SMART. B) 1H NMR (500 MHz, DMSO-d6) 
spectrum of P-SMART. C) Particle size distribution of P-SMART by dynamic light 
scattering (DLS). The mean particle size of P-SMART was 71.51±0.47 nm. D) In vitro 
drug release profile of P-SMART. Concentration of released SMART-OH at each time 
point was measured by HPLC and drug release profiles were represented as the mean 
± SEM (n=3). P-SMART showed a slow but sustained release of SMART-OH at neutral 
and acidic condition. 
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4.3.6 Inhibition of colony formation  
The inhibitory effect of SMART-OH and P-SMART on tumorigenic potential 
in melanoma cells was determined by colony formation assay. The parent drug 
SMART-OH greatly reduced colony formation compared with the control group in 
both cell lines. Meanwhile, long-term treatment of P-SMART allowed much amount 
of conjugated drug to be released from the conjugate and then expose to 
melanoma cells, which resulted in significant anti-proliferative effect. Treatment of 
A375 with P-SMART at a dose of 75 nM reduced colony formation by 94.5% 
compared to the control and treatment of B16-F10 cells with 200 nM P-SMART 
reduced colony formation by 79%. The doses of P-SMART in this assay were far 
below the IC50 of P-SMART in cytotoxicity assay (Figure 30B). 
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We also determined the inhibitory effect of SMART-OH and P-SMART on 
cell invasion using B16-F10 cells. At a dose of 0.5 μM, both parent drug and 
prodrug showed effective inhibition of cell invasion. Treatment of SMART-OH 
suppressed 87% of cell invasion while the ability of P-SMART to prevent cell 
invasion was slightly less with 73% of cell invasion blocked at 24 h (Figure 31). 
 
Figure 30. Cytotoxicity and colony formation assay. A) Cytotoxicity of SMART-OH 
and P-SMART was determined in A375 and B16-F10 cells for 72 h. The IC50 of P-
SMART was 0.75 μM in two cell lines. B) To determine colony formation of melanoma 
cells, 250 cells per well were seeded to 6-well culture plates. At 24 h, drug formulations 
were added and at 7 days, cell colonies were fixed, stained and counted. The long-
term treatment of P-SMART resulted in significant anti-proliferative effect. Data 
represented as the mean ± SEM (n=3). *p<0.05, **p<0.01 compared to Control. 
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4.3.7 Effect of P-SMART on cell cycle and apoptosis 
The effect of P-SMART on cell cycle and apoptosis was determined by PI-
staining using A375 and B16-F10 cells. There was observable G2/M phase arrest 
after treatment of these cells with P-SMART for 48 h and the % of cells in G2/M 
phase was augmented in a dose dependent manner. Specifically, the number of 
A375 cells increased from 14.9% in the control group to 19.1% with 1 μM of P-
SMART and to 39.0% with 1.5 μM of P-SMART (Figure 32A). Similarly, the % of 
B16-F10 cells increased from 11.3% in the control group to 22.9% with 1.5 μM of 
 
 
Figure 31. Cell invasion assay. B16-F10 cells were treated with either SMART-OH 
(0.5 μM) or P-SMART (0.5 μM, equivalent to parent drug) and allowed to invade 
through Matrigel for 24 h. Results were shown as mean number of invaded cells ± 
SEM (n=3). Treatment of SMART-OH suppressed 87% of cell invasion and P-SMART 
blocked 73% of cell invasion. *p<0.05, **p<0.01 compared to Control. 
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P-SMART and to 53.0% with 2 μM of P-SMART (Figure 32B). In addition, the 
number of A375 cells in sub-G1 phase elevated from 0.04% in the control group 
to 24.0% with 1.5 μM of P-SMART (Figure 32A). The number of B16-F10 cells in 
sub-G1 phase increased from 5.2% in the control group to 28.3% with 2 μM of P-
SMART (Figure 32B). The accumulation of cell population in sub-G1 phase 
indicated that apoptotic cells significantly increased after P-SMART treatment. 
 
 
 
Figure 32. Cell cycle analysis and apoptosis of P-SMART. Cells were treated with 
P-SMART for 48 h, stained with propidium iodide (PI), and analyzed on a flow 
cytometer. A) A375. B) B16F10. Results were expressed as the mean ± SEM (n=3). 
The percent of cells in G2/M phase and sub-G1 phase was augmented in a dose 
dependent manner after treatment with P-SMART. 
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4.3.8 In vivo efficacy in B16-F10 lung metastatic mouse model  
We successfully established a metastatic melanoma model in 8-week-old 
female C57BL/6 albino mice by injecting B16-F10-luc cells via tail vein. At day 10, 
all mice were imaged for luciferase bioluminescence to determine the tumor growth 
rate. The mice whose bioluminescent radiance reached 105 were randomized into 
three groups: 1) control, 2) SMART-OH and 3) P-SMART. All treatments were 
administered intravenously at the equivalent dose of 20 mg/kg SMART-OH. Both 
parent drug and prodrug groups showed inhibition of tumor growth compared with 
the control group. Significantly higher tumor growth inhibition was observed in the 
group treated with P-SMART compared with the group treated with SMART-OH 
(Figure 33 and 34A).  
 
 
Figure 33. In vivo representative bioluminescent images at first day and last 
day of treatments. Mice (n=5) from Control (saline), SMART-OH and P-SMART 
groups were taken bioluminescent images every alternate day during the treatment. 
Images of four mice from each group were shown. 
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In addition, treatment with P-SMART significantly reduced the number of 
lung tumor nodules compared to the control and SMART-OH groups (Figure 34B-
C). The survival study showed that the median survival was 28 days in the control 
group and 31 days in the SMART-OH group. The median survival was significantly 
prolonged (38 days) when mice were treated with P-SMART (Figure 34D). 
 
 
Figure 34. In vivo efficacy of SMART-OH and P-SMART in B16-F10 lung 
metastatic animal model. Mice received saline, 20 mg/kg SMART-OH or 20 mg/kg 
P-SMART intravenously once every three days for a total of five times when the 
radiance of tumor had reached 105 (day 10 after tumor implantation). A) Radiance 
intensity plot of all groups was measured from day 10 to day 24. Data represented as 
the mean ± SEM (n=5). B) Representative tumors of each group were excised after 
sacrificing the mice at the end of the efficacy study. Significantly higher tumor growth 
inhibition and less number of lung tumor nodules was observed in the group treated 
with P-SMART compared to SMART-OH treated group. C) The weight of mouse lungs 
from each group was measured at the end of the study. D) Survival analysis of control 
group, SMART-OH group and P-SMART group. The median survival was 31 days in 
SMART-OH group and 38 days in P-SMART group while in control group median 
survival was 28 days. 
 
 
 
 
 
 
89 
 
Hematoxylin and eosin (H&E) stain of lung tissues confirmed the extensive 
metastasis throughout the lung lobe in the control group and the inhibition of 
metastasis and proliferation of tumor cells in the treated groups. As compared with 
the control and parent drug groups, the lung samples from P-SMART treated group 
exhibited alveolar lumen with limited mass of metastatic cells (Figure 35A). 
Furthermore, cleaved caspase-3 stain indicated the induction of significant 
apoptosis by treatment of P-SMART compared to the treatment of SMART-OH 
(Figure 35B). Additionally, the chronic toxicities of these treatments were also 
evaluated by histological analysis of the major organs (Figure 35C). No obvious 
histological changes were observed in the livers, spleens, kidneys and hearts from 
all the treated groups, which suggested that mice tolerated all treatments well. 
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Figure 35. Analysis of lung samples by hematoxylin and eosin (H&E), Caspase 
3 stain and analysis of major organs by H&E stain. Lung samples from control, 
SMART-OH and P-SMART treated groups were excised, fixed and immunostained for 
A) H&E and B) Caspase 3. In control group the metastasis was throughout the lung 
lobe but in the treated groups the metastasis and proliferation of tumor cells was 
inhibited. Cleaved caspase-3 stain indicated significant the induction of apoptosis by 
P-SMART. C) Organ samples from three groups were excised, fixed and stained for 
H&E. No obvious histological changes were observed in the livers, spleens, kidneys 
and hearts from all the treated groups. 
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4.4 DISCUSSION 
Conventional therapies of melanoma such as dacarbazine (DTIC) and 
combination of paclitaxel and carboplatin are small molecular weight drugs, which 
are rapidly eliminated from the circulation, requiring frequent dosing, leading to 
increased risk of side effects. From a clinical standpoint, many anticancer agents 
that are hydrophobic require appropriate drug delivery system to help them reach 
tumors after systemic administration. To solve this problem, hydrophobic drugs are 
encapsulated into liposomes, nanoparticles and micelles. However, physical 
encapsulation into these nanoparticulate systems usually results in fast drug 
release with burst effect. This means higher initial drug loading is needed because 
most drugs should ideally be released at the disease site to reduce their adverse 
effects. In contrast, chemical conjugation of drugs to polymers or lipids prevents 
immediate drug release during the transportation of polymer-drug conjugates and 
provides long-term sustained drug release (Figure 29D). Therefore, conjugation 
of a drug to the polymer prolongs drug circulation and enhances therapeutic 
efficacy. So far polymer-drug conjugates with linear backbone have undergone 
clinical evaluation, such as poly(ethylene glycol) (PEG), poly[N-(2-
hydroxypropyl)methacrylamide] (PHPMA) copolymers, dextran and poly(glutamic 
acid) (PGA) [61-63]. 
We previously physically encapsulated SMART-100 into poly(ethylene 
glycol)-b-poly(D,L-lactide) (PEG-PLA) micelles by film dispersion.[98] As expected, 
drug loading in these physically drug encapsulated micelles was 1.5%. To increase 
drug loading, in previous studies we conjugated gemcitabine or paclitaxel to 
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mPEG-b-PCC, and in the current study we conjugated a novel microtubule inhibitor, 
SMART-OH, to the copolymer.  
PEG was used as a hydrophilic block for synthesizing methoxy-poly 
(ethylene glycol)-block-poly (2-methyl-2-carboxyl-propylene carbonate-graft-
dodecanol) copolymer. To form micelles, we need to maintain a delicate balance 
between hydrophilic and lipophilic components of the copolymer. Since the 
molecular weight of our polymer is in the range of 10,000-11,000 Da, we chose 
PEG of 5000 Da for synthesizing this polymer before conjugating our drug SMART-
OH. If we use PEG of 2,000 Da, we could not have conjugated SMART-OH as 
much as what we have done in this work, otherwise no micelles could be formed. 
This PEG length helps us maintain higher HLB easily and allows us conjugating 
large amount of SMART-OH. The attachment of dodecanol (DC) also enhanced 
requisite hydrophobicity to form micelles of polymer-drug conjugate. Our polymer-
drug conjugation system offers the following distinct advantages: a) PEG corona 
on the polymer imparts stealth property; b) conjugation ensures in vivo stability and 
no premature drug release in the circulation; c) small size of this conjugate 
facilitates the EPR effect to maximize drug delivery to the tumor. Therefore, these 
polymer-drug conjugate showed increased stability and antitumor effect compared 
to parent drugs.  
Microtubule targeting agents that alter microtubule dynamics have been 
developed as anticancer drugs for more than several decades, and they have 
achieved exceptional clinical success acting as essential roles in combination 
therapy and adjuvant therapy [102-104]. These compounds are currently classified 
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as microtubule stabilizers and destabilizers based on their function on microtubule 
mass at high concentrations. Stabilizing agents such as taxanes, epothilones, 
discodermolide, laulimalide, peloruside A, etc., enhance tubulin polymerization 
and block microtubule dynamics [105]. On the other hand, microtubule-
destabilizing agents suppress tubulin polymerization and can be further 
characterized into two groups: vinca-domain binders and colchicine-domain 
binders. Although the wide application of microtubule inhibitors is observed, there 
is urgent need to overcome several emerging challenges including drug-resistance 
and neurotoxicity [106,107].  
In this study, we synthesized a novel microtubule destabilizer, SMART-OH, 
with a hydroxyl group for conjugation with the copolymer (Figure 27). Molecular 
modeling suggested strong interactions between SMART-OH and the tubulin 
dimer, with the phenolic moiety forming a strong hydrogen bond interaction to 
Val315 in tubulin, in addition to the other two hydrogen bonds and hydrophobic 
interactions between SMART-OH and tubulin dimer (Figure 28A). Further, in vitro 
tubulin polymerization assay confirmed experimentally that SMART-OH effectively 
disrupted tubulin polymerization, serving as a potent microtubule-targeting agent 
(Figure 28B). It is also known that microtubule-targeting agents suppress 
microtubule dynamics leading to cell cycle arrest at the mitotic phase. In cell cycle 
analysis, cells were arrested in G2/M phase after treatment with P-SMART (Figure 
32), which confirmed that the mechanism of action of P-SMART was through 
destabilization of microtubules. Treatment of P-SMART also resulted in cell 
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accumulation in sub-G1 phase indicating cell apoptosis and DNA damage was 
induced by P-SMART treatment.  
In addition to its effects on microtubules, P-SMART demonstrated other 
anticancer activities in cytotoxicity, colony formation and cell invasion assays. As 
expected, P-SMART resulted in lower toxicity in A375 and B16-F10 cells when 
compared with the parent drug SMART-OH in a dose dependent manner. The IC50 
of P-SMART was 0.75 μM in both cell lines which was about 10-fold higher than 
SMART-OH in A375 cells and 4-fold higher in B16-F10 cells (Figure 30A). This 
finding is in good agreement with previous reports suggesting that conjugated 
anticancer drugs have higher IC50 than their corresponding parent drugs due to 
slow drug release kinetics [108,109]. Unlike cytotoxicity assay, SMART-OH and P-
SMART showed nearly equivalent activity in the colony formation assays (Figure 
30B) likely due to the 7-day incubation period, which provided P-SMART with more 
time for cellular uptake and drug release. Therefore, the difference in anticancer 
effect between free drug and conjugated drug was reduced and this result 
demonstrated that the potency of SMART-OH was maintained after conjugation. 
As discussed above, melanoma has high metastatic propensity and easily 
metastasizes to other organs. Thus, we did a transwell invasion assay to determine 
whether SMART-OH and P-SMART can impede the migratory potential and the 
invasive property of melanoma cells. Both SMART-OH and P-SMART showed 
significant cell invasion inhibition (Figure 31), which confirmed this drug had good 
anti-metastatic properties in vitro.  
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To investigate in vivo efficacy of SMART-OH and P-SMART, B16-F10-luc 
cells were selected to establish a metastatic model in C57BL/6 albino mice. We 
chose 20 mg/kg as the dose of SMART-OH and P-SMART based on our previous 
studies. We plan to do dose escalation studies and will report in our future 
publication. Both treated groups exhibited promising tumor inhibitory results. 
However, P-SMART treatment showed further enhanced reduction in tumor 
growth rate and tumor size compared with SMART-OH treatment (Figures 33-34). 
Apart from tumor growth suppression, P-SMART also extended mouse survival 
compared to other groups. In addition, a significantly lower burden of metastatic 
cells and increased level of apoptotic cells were found in P-SMART group. H&E 
stain of vital organs demonstrated our formulation carrying P-SMART was well 
tolerated, as other healthy organs did not show obvious histological changes after 
treatments (Figure 35). This is in agreement with our recent report indicating that 
our biodegradable copolymer mPEG-b-PCC as the backbone of delivery system 
has less toxicity and good safety [84]. 
4.5 CONCLUSION   
We have synthesized a novel microtubule destabilizer SMART-OH and its 
corresponding polymer-drug conjugate P-SMART. Our results demonstrate that 
SMART-OH binds to microtubules and suppresses tubulin polymerization. Both 
SMART-OH and P-SMART inhibit in vitro proliferation and invasion of melanoma 
cells. When tested in vivo, P-SMART treatment shows increased anticancer 
efficacy in a melanoma model with lung metastases compared to the control and 
SMART-OH treatment. Future work to fight with metastatic melanoma will focus 
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on improving the potency of novel microtubule inhibitors and optimization of our 
delivery system by including targeting moieties. 
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CHAPTER 5 SUMMARY AND FUTURE DIRECTIONS 
5.1 SUMMARY 
Prostate cancer is one of the most common cancer types and the second 
leading cause of cancer-related death in American men. Although several 
hormone therapies (or androgen deprivation therapy) as first line treatments are 
effective for prostate cancer in early stage, the shrunken tumors might become 
androgen-independent after 18 to 24 month treatment leading to aggressive and 
metastatic forms of prostate cancer, also known as hormone refractory prostate 
cancer (HRPC). Taxane (docetaxel and paclitaxel), used as chemotherapy, is one 
of the standard therapies for HRPC. These anticancer agents have shown 
significant efficacy at initial period of chemotherapy, however, the long-term 
efficacy is limited and patients will suffer from relapse owing to the development of 
chemoresistance.  
One notable cellular mechanism behind chemoresistance is related to the 
presence of cancer stem cells (CSCs). CSCs, a rare and distinct subset of cancer 
cells, have stem-cell-like properties such as self-renewal/differentiation, and 
tumorigenic potentials, which are responsible for cancer initiation, maintenance 
and relapse. The birth of cancer-stem-cell theory can be traced back to 1994. John 
Dick, a Canadian scientist, strikingly identified leukemia stem cell in human 
leukemia and inaugurated a new era of cancer research. With decades of further 
development, it has been established that CSCs are found in many other types of 
cancer including breast, ovary, prostate, pancreas, colon cancer and melanoma. 
A growing body of evidence suggests that several molecular signaling pathways such as 
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Sonic Hedgehog (Hh) signaling, Notch signaling and Wnt/β-Catenin signaling mainly 
involve in the initiation and development of CSCs. Therefore, in Chapter 2 and 3 we 
studied the combination therapy of microtubule inhibitor (paclitaxel or QW-296) 
and Hh signaling inhibitor (Cyclopamine or MDB5) to overcome drug resistance 
and improve the therapeutic effect of chemoresistant prostate cancer. Since both 
tubulin inhibitors and Hh signaling inhibitors are highly hydrophobic, we also 
developed PEG-based polymeric drug conjugates or polymeric micelles to deliver 
these anticancer drugs and enhance therapeutic efficacy. Our results indicated 
that the combination formulations could synergistically work together with different 
mechanisms of action and suppress chemoresistant prostate tumor growth in vitro 
as well as in orthotopic mouse model.  
Melanoma originated from melanocytes is the most aggressive type of skin 
cancer. It has high potential to metastasize through lymph nodes to the distant 
sites of the body, especially the lungs, liver and brain. Systemic chemotherapy 
remains the mainstay of its treatment; however, multidrug resistance (MDR) and 
dose limiting toxicity restrict the efficacy of current chemotherapeutic drugs. We 
recently synthesize a novel microtubule destabilizer, substituted methoxybenzoyl-
ary-thiazole (SMART-100) and it can effectively circumvent MDR that hinders the 
clinical efficacy of existing tubulin inhibitors. Nevertheless, poor water solubility of 
SMART-100 requires co-solvent delivery for its systemic administration, which 
associates with toxicity to liver and kidney, hemolysis and peripheral neuropathies. 
Therefore, in Chapter 4, to solve this problem and prolong circulation of this small 
molecule, we developed methoxy-poly (ethylene glycol)-block-poly (2-methyl-2-
carboxyl-propylene carbonate-graft-SMART-graft-dodecanol) (P-SMART) with 
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high drug payload of SMART. This polymer-drug conjugate self-assembled into 
micelles with small particle size and the release of SMART was slow but at 
appreciable rate. Similar with its parent drug, P-SMART killed 60-70% of A375 
cells and B16-F10 cells at 1 µM of equivalent concentration of SMART and 
arrested cell cycle in G2/M phase. In addition, P-SMART significantly suppressed 
colony formation and cell invasion of melanoma cells. We established lung 
metastatic melanoma in C57/BL6 albino mice by injecting B16-F10-luc through tail 
vein. During the treatments, there was maximum inhibition of tumor growth in P-
SMART group compared with control group and parent drug group. In conclusion, 
this novel polymer-microtubule inhibitor conjugate P-SMART has the potential to 
treat lung metastasis melanoma. 
5.2 FUTURE DIRECTIONS 
The preliminary findings reported in the prostate cancer projects and 
melanoma project confirmed that the combination strategy or the novel tubulin 
destabilizer had the potential to treat chemoresistant prostate cancer or metastatic 
melanoma. The PEG-based polymeric formulations could promote the delivery 
efficiency of these anticancer agents to the tumor sites leading to enhanced 
therapeutic efficacy compared with their corresponding parent drugs. However, 
from a perspective of clinical translation, our current polymeric delivery platform 
could be improved from the following aspects.  
First, it is known that nano-sized agents could preferentially leak into tumor 
sites through permeable tumor vasculature; nevertheless, the EPR effects as 
known as passive targeting are relatively moderate and at the same time a small 
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portion of drugs can also extravasate into normal tissues. Therefore, in the future 
we will attach targeting moieties such as peptides or antibodies to the polymeric 
platform to develop a specific active-targeting drug delivery system, which can 
reduce off-target delivery and release more anticancer drugs at the site of action.  
Furthermore, besides targeting efficiency, the drug release profile is another 
limiting factor for therapeutic efficacy, which suggests the composition of 
formulation can be designed to release the drug according to the tumor 
microenvironment or the therapeutic needs. Since the pH of tumor site is usually 
acidic, in future studies we will modify polymer components to be sensitive to acidic 
environment allowing pH-triggered drug release.  
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